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1.1 General Introduction 
 
During the development of the central nervous system (CNS), and in several 
neurological disorders, remodeling or alteration of neuronal networks occurs. These events 
are associated with tissue recruitment of mononuclear phagocytes and transient 
accumulations of brain macrophages. For instance, appearance of macrophages is an early 
response to experimental tissue lesions of various origins including ischemia (1), 
mechanical trauma (2), infections (3), autoimmune inflammation (4), or neuronal death 
induced by local injections of neurotoxins (5). Beyond the obvious task of cell debris 
removal, histological and neuropathological observations raise the issue of influence of 
macrophages on neuronal death and morphological remodeling of neurons. These cells 
have been proposed to play a pathogenic role in stroke and trauma and a variety of CNS 
diseases, such as multiple sclerosis (6), Parkinson’s disease (7), Huntington’s disease (8), 
human immunodeficiency virus type 1-associated dementia (HAD) (9), Alzheimer’s 
disease (AD) (10) and recently also in Creutzfeldt-Jakob disease (11,12). Indeed, strategies 
to reduce the recruitment of macrophages into the CNS reduced ischaemic injury in the 
spinal cord (1) and suppressed experimental allergic encephalitis (4), the animal model 
disease for multiple sclerosis. The precise mechanisms by which macrophages mediate 
neuronal cell injury in these CNS disorders are still incompletely understood. Macrophages 
also play a role in neuroregeneration. For instance, macrophages are known to produce 
neurotrophic factors like brain-derived neurotrophic factor (BDNF) and nerve growth factor 
(NGF) (13). Indeed, a study by Boven et al. shows an elevation of NGF and basic fibroblast 
growth factor (bFGF) in perivascular areas of HAD patients’ brains, suggesting that these 
molecules may exert different actions depending on the area in which they are generated; 
when produced by reactive astrocytes throughout the brain parenchyma they may function 
as a neuronal survival factor whereas in perivascular areas they may be associated with 
endothelial injury (14). 
 
1.2 Introduction to Alzheimer’s disease: clinical and pathology 
 
AD is a dementing disorder causing severe and permanent impairment of multiple 
cognitive faculties (15). The definition of AD may vary according to the purposes for which 
it is used. However, the most broadly applied criteria for the clinical definition of AD was 
introduced by the work group of the National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA) in the United States (15). According to these criteria AD can be 
classified into definite, possible and probable levels of diagnostic certainty. 
Neuropsychological tests together with documented standardized mental status assessments 
are required and are used for establishing dementia. Supportive symptoms, although not 
required for diagnosis, are deficits in language, perceptual recognition and impaired 
activities of daily living; a familial history of a similar disorder, especially if confirmed 
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pathological and normal or nonspecific routine tests such as spinal fluid examination and 
electroencephalography (16). 
Neurodegenerative disorders, including AD, produce their clinical symptoms by 
disrupting to various degrees the normal circuitry of the brain. The histopathology of AD 
includes neuritic plaques, neurofibrillary tangles, AMY plaques, loss of synapses and 
neurons, granulovascular degeneration and amyloid angiopathy. 
Three types of amyloid-related plaques are recognized in the brain of the AD patient 
(17). Plaques with large or poorly circumscribed amyloid are frequently referred to as 
diffuse plaques. These plaques are thought to represent the earliest stages of plaque 
formation and are found in areas of the brain that are not symptomatic in the course of the 
disease, such as the cerebellum and throughout the cerebral hemispheres. The neuritic 
plaque is a spherical structure with a diameter of 50 to 200 µm and consist of a central core 
of amyloid-β proteins surrounded by dystrophic neurites (16). Reactive microglia and 
astrocytes are found within the plaque and at the plaque periphery (18). The third type of 
plaques are those that are considered to be composed exclusively of amyloid and are 
designated amyloid plaques. Classically they are described as ‘burned out’ plaque. 
Another important and widely spread pathological change in AD is the 
neurofibrillary tangle. Neurofibrillary tangles consist of paired helical filaments that occupy 
the neuronal cell body and may extend into dendrites but do not occur in the axon. Paired 
helical filaments consist of protofilaments arranged to form a tubule and containing 
abnormally phosphorylated τ-protein. 
Making a definitive diagnosis of AD requires a histopathological examination and 
until recently criteria were based on the number of neuritic plaques present in the cortex in 
relation to age-related standards (19). These criteria have been revised by a work group 
sponsored by the National Institute on Aging and the Reagan Institute of the Alzheimer’s 
Association in the United States and now emphasize on the presence of both neuritic 
plaques and neurofibrillary tangles in the neurocortex (20). 
Next to amyloid-containing plaques and tangle-bearing neurons, the brains of AD 
patients have abundant AMY plaques. They are recently described as plaques composed of 
a protein that is coexistent with but distinct from hyperphophorylated τ-protein. AMY 
plaques contain no amyloid, although they are found only in brains that also have amyloid 
and occur in the same brain regions as amyloid plaques (21). 
 
1.3 Amyloid-beta 
 
Aβ is generated by sequential endoproteolysis of the amyloid precursor protein 
(APP) (22) and is constitutively secreted by many cells throughout life (23). APP is a large 
single spanning (type 1) membrane molecule with a yet undefined cellular function. 
Following synthesis in the endoplasmatic reticulum (ER), the protein is transported to the 
cell surface via the secretory pathway. In Golgi as well as during reinternalization in 
endosomes, APP is cleaved by β-secretase in its N-terminal domain (24-27). This cleavage 
results in the release of soluble APPβ (sAPPβ) into the extracellular fluids and generates 
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the membrane-associated C-terminal APP fragment C99 (Figure 1) (28). C99 is 
subsequently cleaved by γ-secretase in the C-terminal part of its transmembrane domain, 
liberating Aβ into the extracellular space (29). Heterologic cleavage by γ-secretase results 
in the production of Aβ peptides that vary in length between 39 to 43 amino acids (23). The 
most abundant form of Aβ is the Aβ(1-40) peptide that accounts for approximately 90% of 
the secreted Aβ peptides (30,31). Although Aβ(1-40) is fibrillogenic and present in neuritic 
plaques, it is not as neurotoxic as Aβ(1-42) and is not able to aggregate (32-35). This final 
feature is important, since aggregation of Aβ fibrils is a requisite for the formation of 
neuritic plaques.  
APP can also be processed by α-secretase that is active in late Golgi, transport 
vesicles and at the cell surface (24,25,36-40). α- and β-secretase compete for the APP 
substrate (24,25,41), although α-secretase generally cleaves APP in earlier compartments 
than β-secretase. α-Secretase cleavage results in the secretion of the large N-terminal 
fragment sAPPα and generates the membrane-bound C83 fragment (Figure 1) (42,43). α-
Secretase processing of APP precludes the formation of Aβ, since it cleaves in the middle 
the Aβ domain (44,45). C83 is a substrate for γ-secretase that releases the p3 peptide from 
the membrane (46,47). The p3 peptide is probably non-pathogenic since this peptide is 
smaller than its longer variant Aβ and therefore not able to aggregate into plaques. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
Generation of the amyloid-β peptide. The amyloid precursor protein (APP) is first cleaved by either α- or 
β-secretase, resulting in the release of soluble APPα and β (sAPPα and sAPPβ), and in the generation of 
membrane-associated C83 and C99. A second endoproteolytic cleavage that is carried out in the lipid bilayer, is 
mediated by γ-secretase. This cleavage results in the secretion of either Aβ (product of β- and γ-secretase) or p3 
(product of α- and β-secretase) peptides in the extracellular fluids. 
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1.4 Mutations in Alzheimer’s disease 
 
AD can be divided into two genetically distinct types: familial AD (FAD) in which 
the disease is transmitted as an autosomal-dominant trait, and sporadic AD (SAD) which 
shows modest familial clustering and probably results from the synergistic action of genetic 
and environmental factors (48,49). There are no pathological and clinical features that 
distinguish FAD from SAD, except that FAD generally has an earlier age of onset. Genetic 
and environmental factors contribute equally to the development of both forms of AD 
(48,49). Most patients with AD (90%) suffer from late onset AD that occurs sporadically 
(50). Three modifier genes have been identified that show modest familial clustering in 
SAD. Inheritance of these genes results in an increased susceptibility for AD, but does not 
imply that the carrier will develop the disease. The best example of a modifier gene is the 
ε4 allele of the apoE gene on chromosome 19 that is estimated to account for approximately 
50 % of the genetic component of AD (51). 
FAD accounts for only a minority of all AD cases and is associated with inheritance 
of autosomal dominant genes. Genetic linkage studies of different FAD families have given 
valuable insight in the pathogenesis of AD. Analysis of the FAD-causing mutations in APP 
showed that all mutations resulted in an increased production of Aβ42 (52-54), the main 
component of neuritic plaques. This increased generation of Aβ is caused by either 
stimulation of the β-/γ-secretase cleavage or by inhibition of α-secretase processing. 
Mutations in the APP gene account only for small proportion (<3%) of all FAD-linked 
mutations and result in an average age of onset before 65 years (55-58). The majority of the 
FAD causing mutations however, are found in the two presenilin genes PS1 and PS2 (59-
61). PS1 is located on chromosome 14 and is estimated to account for 70% of all FAD 
cases (62-64). FAD mutations in the PS1 gene are associated with the most deleterious 
form of AD (65), with a mean age of onset that varies between 30-60 years. In contrast to 
PS1, only 2 FAD-linked mutations have been found in the PS2 gene on chromosome 1. The 
age of onset of patients with FAD mutations in PS2 lies between 50-70 years (60). 
Interestingly, all FAD-linked mutations found in the PS1 and PS2 genes result in the same 
alternation as the mutations in APP: an increased generation of the Aβ42 (66). 
 
1.5 Role of microglia in Alzheimer’s disease 
 
Inflammation in AD appears only to arise from within the CNS, with little or no 
involvement of lymphocytes and monocytes beyond their normal surveillance of the brain 
(67). How and when inflammation arises in the course of AD has not yet been fully 
resolved. Throughout the years, AD inflammation research has been focused on various 
subjects including cytokines, complement, chemokines, growth factors, oxidative stress, 
microglial activation, astrocyte reactivity. However, it is important to realize that 
inflammatory reactions are highly interactive and almost never occur in isolation from each 
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other. In the AD brain the Aβ proteins, neurofibrillary tangles and neuronal degeneration 
seem to be the most likely sources of inflammation. From here a bewildering number of 
subsystems come into play, each with multiple interactions with other subsystems. These 
interactions make it possible for one set of mediators to activate most others. Presently 
there is no reason to believe that any one mechanism is more primary than the others.  
As pointed out earlier neuritic plaques are composed of a core of dense aggregated 
Aβ peptides and are surrounded by microglia and astrocytes, in contrast to diffuse plaques 
which seem not to be surrounded by those cells (68). Although Aβ can act as a potent and 
direct neurotoxic agent (69-72) an increasing amount of evidence show that neuritic 
plaques elicit a cascade of cellular events which lead to neuronal pathology (73,74). In the 
late nineteen eighties the group of McGeer and the group of Rozemuller and Eikelenboom 
showed that reactive microglia, which show increased immune-labeling for the human 
leukocyte antigen (HLA-DR) and for glycoproteins of the leukocyte function-associated 
antigens (LFA-1) family, i.e. LFA-1, P150,95 and iC3b-receptor, are closely associated 
with neuritic and amyloid plaques, but not with diffuse plaques (7,75-78). Using electron 
microscopic reconstruction Wisniewski and coworkers have also noted interactions 
between microglia and neuritic plaques (79). Because of their altered morphology and 
increased expression of MHC-II, cytokines, chemokines and complement these microglia 
are, like microglia in a variety of neuropathologic conditions, appropriately referred to as 
being activated (80-84). However, there is one stumbling block. The in-vivo situation and 
the in-vitro situation are not per definition the same. Products expressed by microglia or 
cells used as a model for microglia in-vitro might not be produced in the brain. For example 
astrocytes in culture express MHC-II but they do not so in the brain (85-87). Therefore in 
the conventional immunological sense astrocytes in AD cortex might not be an activated 
astrocyte. 
Many groups have performed a lot of effort in trying to unravel the role of the 
microglia. Herein a lot of research have been focused on the neurotoxic properties. 
Microglia have been found to produce interleukin-1 (IL-1), IL-1β, IL-6, complement C3, 
tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-β) and interferon-γ 
(IFN-γ) when activated (74,88-95). Next to these pro-inflammatory products microglia are 
able to produce neurotoxic products including reactive oxygen species, cytokines and 
secreted proteases (96-98). Moreover, there are also reports that microglia produce 
neurotrophic molecules like nerve growth factor (NGF) and basic fibroblast growth factor 
(bFGF) (99). 
 
1.6 Astrocytes 
 
Like microglia, astrocytes are located at sites of Aβ deposition. Unlike microglia a 
few reactive astrocytes are present in virtually all diffuse plaques. The highest densities 
however are in neuritic plaques. Astrocytes are rarely associated with ‘burned out’ plaques 
(100). The positioning of astrocytes in plaques differs from that of microglia. Astrocytes 
somas form a corona at the edge of the neuritic halo that, in turn, may surround a dense 
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core Aβ deposit. Processes from the astrocytes cover and interact with the neuritic layer 
(100), in a manner reminiscent of glial scarring and there is, in fact, recent evidence that 
plaque-associated astrocytes may be creating barriers. When microglia are presented with 
naked Aβ depositions onto the culture substratum they can readily clear the deposit. 
However, when Aβ deposits are first presented to astrocytes they deposit proteoglycans that 
greatly inhibit the microglial attack (101). Astrocytes may therefore impair the natural 
ability of microglia to clear plaques. 
 
1.7 Intracellular pathways 
 
Research of the microglial signal transduction pathways mediating the neurotoxic 
response of Aβ has revealed the mitogen-activated protein kinase (MAPK) superfamily 
members ERK1/2 and p38 MAPK as important mediators (102,103). Besides, an increasing 
amount of evidence shows that the transcription factor nuclear factor-κB (NF-κB) can be 
stimulated in microglia by Aβ(25-35) (104,105). Upregulation of ERK1/2 and p38 MAPK 
can lead to the activation of numerous transcription factors in their turn leading to the 
activation of cytokines and neurotrophic factors. Activation of NF-κB can lead to the 
transcription of genes expressing TNF-α, IL-1, IL-6, monocyte chemoattractant protein-1 
(MCP-1) and nitric oxide (NO) synthase (reviewed in (106)). The production of reactive 
oxygen species as a neurotoxic response of Aβ in microglia seems to involve the NADPH 
oxidase system (96,107). Protein kinase C is thought to be involved as a mediator of the 
NADPH oxidase system (108). 
It remains unclear how above-mentioned signal transduction pathways that mediate 
the neurotoxic response are stimulated by Aβ. Presumably Αβ induces these cellular effects 
by engaging a binding protein (or proteins) presented by plasma membranes. The receptor 
for advanced glycation end products (RAGE) is described to be a possible candidate. It was 
first reported in 1996 that besides binding advanced glycation end products and amphoterin, 
RAGE is able to mediate Aβ-induced cellular activation in macrophages and in neurons 
(109,110). Another receptor capable of binding Aβ and present on macrophages is the class 
A scavenger receptor (111,112). Because Aβ(25-35) is capable of blocking the binding of 
Aβ(1-40/42) to RAGE and class A scavenger receptors on the one hand and reports of 
groups showing that the 1-16 domain of the Aβ protein is most likely to be involved in the 
binding of the protein to the macrophages (113-115) on the other hand and additional 
reports showing that RAGE and class A scavenger receptors are not involved in the Aβ-
stimulated ERK1/2 activation (102) it remains unclear how Aβ is coupled to signal 
transduction pathways. 
The cytokines and reactive oxygen species released by microglia / macrophages can 
not only be direct neurotoxic, they can also activate surrounding astrocytes. Astrocytes can 
be shown to be associated with many, but not all senile plaques. They are most closely 
associated with plaques with a dense amyloid core and an attendant microglial reaction. 
Stimulation of astrocytes by IL-1β, TNF-α and reactive oxygen species activates NF-κB 
(116,117). Moreover, in vitro studies show that Aβ(1-42) is capable of activating NF-κB 
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and stimulating production of IL-1β and NO in rat astrocytes (118,119). On the other hand, 
it has also been shown that activity of iNOS in microglial cells is inhibited by the presence 
of astroglial cells, probably involving TGF-β (120). More important, astrocytes have also 
been shown to inhibit phagocytic properties of microglial cells (101). 
 
1.8 Chemokines 
 
Since the discovery of the role of the CCR5 chemokine receptor in HIV 
pathogenesis (121,122) the status of chemokines and their receptors has raised 
considerably. To date, the known chemokine family in humans consists of approximately 
50 ligands and 20 G protein-coupled receptors. Bone marrow-derived cells are the principle 
targets of chemokines. Because motility is an essential part of their function, chemokines 
play a central role in leukocyte physiology by controlling basal and inflammatory 
trafficking. But, chemokine receptor activation is not only responsible for motion, it can 
also play a role in gene transcription, infections, angiogenesis, mitogenic effects or 
apoptosis. Moreover, many other cell types also express chemokine receptors. These cells 
include smooth muscle cells, epithelial cells, neurons and stromal cells. Thus, next to 
localizing cells of the immune system to specific places, chemokines might be involved in 
aspects of tissue homeostasis. 
Chemokines are small, about 8~14 kDa, secreted molecules that exhibit very 
specific cysteine motifs in their amino acid sequence. Almost all members have four 
cysteines, and depending on the motif of the first two residues they have been classified 
into CXC, CC, C, and CX3C classes. The only exception is lymphotactin which has only 
two cysteine residues (123). Two disulfide bonds are formed between the first and the third 
Cys and the second and the fourth residues. In addition the CXC family has been 
subdivided into two groups, depending on the presence of the ELR motif preceding the first 
cysteine: the ELR-CXC chemokines and the non-ELR-CXC chemokines. Chemokine 
receptors are G protein-coupled, seven-transmembrane receptors. Based on the chemokine 
class they bind, the receptors have been named CXCR, CCR, XCR, and CX3CR (124).  
 
1.9 Scope of this thesis 
 
Although much research has been done on the physiology of the neuritic plaque, the 
exact mechanisms responsible for the decay of the neurons surrounding this plaque is still 
not clear. Moreover, almost all research has been focused on and is still focused on 
interpreting the processes occurring within the neuritic plaque. The answer to the question 
how are these glial cells attracted towards the plaque is still a black box. Because in-vivo 
microglial cells and astrocytes are in immediate vicinity, the research presented in this 
thesis has not just been focused on the response of the macrophage when activated by 
amyloid-beta. More important the effect of the astrocyte on the response of the macrophage 
has therefore been investigated. Besides, the interaction of the macrophage and the 
Introduction 
 9 
astrocyte has been a pivotal element in resolving the role of these cells in the inflammatory 
response. In addition the role of several signal-transduction pathways that are pivotal in the 
macrophage-mediated inflammatory response towards Aβ are investigated. 
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Introduction 
 
Previously, we and others have shown that Aβ, which is the full-length homologue 
to the Aβ actually deposited in the Alzheimer’s disease brain, is capable of priming and/or 
triggering the respiratory burst of cultured rat microglial cells (1). Using primary cultures of 
human monocyte-derived macrophages as a model of human microglial cells, we recently 
discovered that the amino-terminus of Aβ is critical for the cellular binding and consequent 
activation of the phagocytic respiratory burst (Van Muiswinkel et al., unpublished 
observations). Furthermore, in line with previous studies of Giulian and colleagues (2,3), 
we found that Aβ(1-16) behaves like a pharmacological antagonist. Thus, using flow 
cytometry with Aβ(1-42)-FITC and lucigenin-enhanced chemiluminescence, it was found  
that Aβ(1-16), which has been described as containing a cell attachment domain (2,3), 
inhibited both the cellular binding and the Aβ(1-42)-induced release of superoxide anion in 
human macrophages. In the present study, we have used the same experimental model to 
investigate the effects of Aβ(25-35) on the Aβ(1-42)-induced oxidative burst. 
 
Materials and methods 
 
Amyloid-β peptides 
The synthetic Aβ peptides Aβ(1-42) and Aβ(25-35) (Bachem AG, Switzerland), 
prepared as stock solutions in sterile water at a concentration of 500 µM, were stored at –20 
°C. FITC-labeled Aβ(1-42) was prepared by incubating Aβ(1-42) at a concentration of 10 
mg/ml with 0.1 mg/ml FITC in PBS (pH=7.4) for 1 h at 22 °C. Subsequently, using a 1 kDa 
Spectra/Por dialysation membrane, Aβ(1-42)-FITC was dialyzed overnight against PBS to 
remove unbound FITC, diluted to a concentration of 220 µM and stored at –20 °C. 
 
Human monocyte-derived macrophages 
Monocytes were derived from peripheral blood mononuclear cells by Ficoll-Paque 
(Pharmacia Biotech, Sweden) density gradients and purified by centrifugal elutriation as 
described previously (4). Cells were seeded at a concentration of 2x106 cells/ml in Teflon 
Erlenmeyer flasks (Nalgene, USA) and grown as suspension at 37 °C in a humidified 
atmosphere of 5% CO2/95% air. Culture medium was composed of Iscove’s modified 
Dulbecco’s medium (Gibco Life technologies, The Netherlands) supplemented with 10% 
heat-inactivated human AB serum, 2 mM L-glutamine, 19 mM sodium bicarbonate, 10 
µg/ml gentamicin and 10 µg/ml ciprofloxacin. After 7 days, monocyte-derived 
macrophages (MDMs) were harvested from the flasks, washed with Hanks’ balanced salt 
solution (HBSS) and used for the experiments. 
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Superoxide anion production 
Superoxide anion production was measured as lucigenin-enhanced 
chemiluminescence (4). Briefly, cells were transferred to polystyrene vials (2x105/vial), 
placed into a luminometer (Packard Instruments, Belgium) and incubated for 30 min at 37 
°C in HBSS containing 250 nM bis-N-methylacridinum (Lucigenin; Sigma Chemical Co., 
The Netherlands) to assess the spontaneous release of superoxide anions. Subsequently, Aβ 
peptides were added and chemiluminescence (expressed as millivolts) was monitored for 
30-60 min. 
 
Flow cytometry 
For Aβ(1-42)-FITC binding studies, 2x105 cells were incubated at 37 °C with HBSS 
containing 2.5 µM Aβ(1-42)-FITC, either alone or in combination with 50 µM Aβ(25-35). 
After 30 min, the cells were washed with HBSS and fixed for 15 min with PBS containing 
2% paraformaldehyde. Thereafter, flow cytometry analysis was performed by analyzing 
10000 cells per experimental condition on a FACScan flow cytometer (Becton Dickinson 
and Co., USA) equipped with a computer-assisted data analysis system. 
 
Results 
 
Effect Aβ(25-35) on the Aβ(1-42)-induced superoxide anion release 
To investigate the effect of Aβ(25-35) on the Aβ(1-42)-induced superoxide anion 
production, MDMs were incubated with Aβ(1-42), either alone or in combination with 
various amounts of Aβ(25-35). Results are shown in Figure 1. While the spontaneous burst 
amounted to 6.9 ± 1.3 mv, it was found that the respiratory burst was enhanced to 18.8 ± 
0.4 mv by 10 µM Aβ(1-42). Moreover, while Aβ(25-35) did not trigger the respiratory 
burst by itself, Aβ(25-35) dramatically enhanced the Aβ(1-42) release of superoxide anion, 
i.e., in the presence of 200 µM Aβ(25-35) the Aβ(1-42)-induced release amounted to 67.8 ± 
2.1 mv. 
 
Effect of Aβ(25-35) on the cellular binding of Aβ(1-42)-FITC 
To characterize the nature of the aforementioned effects of Aβ(25-35) on the Aβ(1-
42)-stimulated superoxide release, we next investigated the effect of Aβ(25-35) on the 
cellular binding of Aβ(1-42) to human macrophages. Therefore, MDMs were incubated 
with Aβ(1-42)-FITC, either alone or in combination with Aβ(25-35). As shown in Figure 2, 
it was found that 2.5 µM Aβ(1-42)-FITC readily binds to MDMs. Control experiments 
performed at 4 °C or in the presence of 10 µg/ml cytochalasine B revealed that under our 
conditions Aβ(1-42)-FITC accumulates predominantly at the cell surface. Interestingly, 
whereas preincubation of cells with Aβ(25-35) did not have any effect, the cellular binding 
was markedly enhanced when 2.5 µM Aβ(1-42)-FITC was added together with 50 µM 
Aβ(25-35). This phenomenon was even more pronounced when Aβ(1-42)-FITC and 
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Aβ(25-35) were first incubated for 30 min prior to adding the peptides to the cells (Figure 
2). 
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Figure 1 
Effect of Aβ(25-35) on the Aβ(1-42)-induced superoxide anion release from human monocyte-derived 
macrophages. Superoxide anion release was measured in MDMs, either incubated with HBSS (*), 10 µM Aβ(1-
42) (closed triangle), 200 µM Aβ(25-35) (closed diamond) or a combination thereof (x). 
 
Discussion 
 
In summary, the results of the current study demonstrate that the cellular binding of 
Aβ(1-42) and consequent activation of the respiratory burst of MDMs is enhanced in the 
presence of Aβ(25-35). Intriguingly, this effect was only observed when Aβ(1-42) and 
Aβ(25-35) were first preincubated in the absence of cells or when both peptides were added 
as a mixture. Although the nature of this effect is, as yet, largely enigmatic, various cellular 
mechanisms might be implicated. For example, Aβ(25-35) is known to induce changes in 
intracellular calcium homeostasis and/or to trigger tyrosine kinase-dependent intracellular 
signal-transduction pathways (5,6), phenomena which are both thought to be implicated in 
the activation and/or regulation of the respiratory burst (6,7). Thus, in such a way Aβ(25-
35) might be able to prime MDMs for an enhanced Aβ(1-42)-induced respiratory burst. 
Alternatively, the effects of Aβ(25-35) might be due to its direct influence on the 
biophysical properties and/or the assembly state of Aβ(1-42). Particularly since 
preincubation of cells with Aβ(25-35) prior to the addition of Aβ(1-42) did not have any 
effect, in our opinion the latter explanation seems most plausible. Hence, notwithstanding 
the fact that Aβ(25-35) fragment as such does not exists in the AD brain, the results 
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obtained in our study might be relevant in that they provide new insight into the structural 
features required for Aβ-microglia interactions and consequent microglia-driven pathogenic 
mechanisms. 
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Figure 2 
Effect of Aβ(25-35) on the binding of Aβ(1-42)-FITC to human monocyte-derived macrophages. Cells 
were incubated for 30 min with either 2.5 µM Aβ(1-42)-FITC (A), or Aβ(1-42)-FITC together with 50 µM Aβ(25-
35) (B), or preincubated with Aβ(25-35) followed by Aβ(1-42)-FITC (C), or preincubation with a mixture of 
Aβ(25-35) and Aβ(1-42)-FITC (D). 
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Abstract 
 
In this study the intracellular signal transduction pathways leading to the production 
of TNF-α and superoxide anions by amyloid-β-stimulated primary human monocyte-
derived macrophages was investigated. Using Western blotting and specific inhibitors it is 
shown that both ERK 1/2 and p38 MAPK signal transduction pathways as well as PKC are 
involved in the amyloid-β-stimulated superoxide anion production. In contrast, only ERK 
1/2 MAPK seems to be involved in TNF-α production: questioning the connection between 
PKC and ERK 1/2 activation. Our results suggest the use of ERK 1/2 MAPK inhibitors in 
the prevention of macrophage activation in the context of Alzheimer’s disease. 
 
Introduction 
 
One of the characteristics of Alzheimer’s disease (AD) is the presence of 
extracellular depositions in the cortical gray matter (1). These so-called neuritic plaques are 
mainly composed of aggregated amyloid-β (Aβ) peptides. Studies with synthetic Aβ have 
shown that it can act as a potent and direct neurotoxic agent (2-4). Furthermore, neuritic 
plaques are reported to be surrounded by microglia (5-8). Activated microglia, or so called 
brain macrophages, are able to produce neurotoxic factors and a lot of research has focused 
on the ability of Aβ to induce these events. Studies have shown that Aβ is able to induce 
proinflammatory interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and transforming 
growth factor-β (TGF-β) but also neurotrophic molecules like nerve growth factor (NGF) 
and basic fibroblast growth factor (bFGF) in THP-1 monocytes (9-13). Aβ is also reported 
to stimulate the generation of reactive oxygen species (ROS) in rat microglia, THP-1 
monocytes (14-17) and recently also in primary human macrophages (18,19). Moreover, an 
excessive release of ROS not only leads to oxidative stress but may also potentiate the 
inflammatory response, e.g. by triggering redox-sensitive expression of various 
inflammatory genes (20,21). 
The intracellular pathways of Aβ-stimulated microglia leading to the production of 
these neurotoxic products are still largely enigmatic. Research of these signal transduction 
pathways mediating the neurotoxic response of Aβ has revealed the mitogen-activated 
protein kinase (MAPK) superfamily members ERK 1/2 and p38 MAPK to be important 
mediators (22,23). Besides, an increasing amount of evidence shows that the transcription 
factor nuclear factor-κB (NF-κB) can be stimulated by Aβ in neurons (3,21,24) and by 
Aβ(25-35) in microglia (12,12,25). Upregulation of ERK 1/2 and p38 MAPK can lead to 
the activation of numerous transcription factors in their turn leading to the activation of 
cytokines and neurotrophic factors. Activation of NF-κB can lead to the transcription of 
genes expressing TNF-α, IL-1, IL-6, monocyte chemoattractant protein-1 (MCP-1) and 
nitric oxide (NO) synthase (reviewed in (20)). 
In this report the intracellular pathways of Aβ-stimulated monocyte-derived 
macrophages leading to the production of TNF-α and superoxide anions were investigated. 
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Using Westernblot analysis the activation of ERK 1/2, p38 MAPK and protein kinase C 
(PKC) by Aβ was studied. More specific the role of ERK 1/2, p38 MAPK and protein 
kinase C (PKC) in the production of TNF-α and superoxide anions was studied using 
PD098059 (26,27), SB202190 (28,29) and bisindolylmaleimide (30) as specific inhibitors. 
In addition, staurosporine was used to study the role of PKC and protein kinase A (PKA), 
protein kinase G (PKG) and calmodulin-dependant protein kinase (CaM) (31). 
 
Materials and methods 
 
Materials 
The synthetic Aβ peptide Aβ(1-42) was obtained from Genosphere Biotechnologies 
(Paris, France). PKC mouse monoclonal antibody was obtained from Santa Cruz 
Biotechnology (Heidelberg, Germany). ERK 1/2 phospho-specific rabbit polyclonal 
antibody and p38 MAPK phospho-specific rabbit polyclonal antibody were bought from 
New England BioLabs (Frankfurt am Main, Germany). Goat Anti-Rabbit IgG-HRP 
secondary antibody was obtained from Southern Biotechnology Associates (Birmingham, 
AL, USA). PD098059, SB202190 and staurosporine were obtained from Calbiochem (La 
Jolla, CA, USA). Bisindolylmaleimide, gentamycin sulfate and bis-N-methylacridinum 
were purchased from Sigma (Zwijndrecht, The Netherlands). Iscove’s modified Dulbecco’s 
medium was obtained from Gibco Life Technologies (Breda, the Netherlands). 
Ciprofloxacin was bought from Bayer Pharmaceuticals (Mijdrecht, The Netherlands) and 
Ficoll-paque from Pharmacia Biotech (Uppsala, Sweden). 
 
Amyloid-β 
Lyophilized synthetic Aβ(1-42) peptide, initially dissolved at a concentration of 1 
mM in sterile double-distilled pyrogen-free water, was aliquoted and stored at –20 °C. 
 
Cells 
Monocytes were derived from peripheral blood mononuclear cells by Ficoll-paque 
density gradients and purified by centrifugal elutriation as described previously (32). Cells 
were seeded at a concentration of 2 x 106 cells / ml in Teflon Erlenmeyer flasks (Nalgene, 
USA) and grown as suspension at 37 °C in a humidified atmosphere of 5% CO2 / 95% air. 
Culture medium was composed of Iscove’s modified Dulbecco’s medium supplemented 
with 10% (v/v) heat-inactivated human AB serum, 2 mM L-glutamine, 19 mM sodium 
bicarbonate, 10 µg/ml gentamicin and 0.5 µg/ml ciprofloxacin. After 7 days, monocyte-
derived macrophages (MDMs) were harvested from the flasks, washed with Hanks’ 
balanced salt solution (HBSS) and used for experiments. 
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Westernblot analysis of Aβ-stimulated ERK 1/2, p38 MAPK and PKC activation 
To measure ERK 1/2, p38 MAPK and PKC activation, sodium dodecyl sulfate 
(SDS)-polyacrylamide gel electrophoresis was performed, followed by Western blotting. 
Blots then were stained with a purified rabbit antiserum containing antibodies directed 
against Thr202- and Tyr204-phosphorylated (i.e., active) ERK 1 (p44) and ERK 2 (p42) or 
Thr180- and Tyr182-phosphorylated p38 MAPK or with a purified mouse antiserum 
containing antibodies against a highly conserved epitope within the hinge region of PKC. 
First macrophages were stimulated with 10 µM Aβ(1-42) for the indicated times (Fig. 1) at 
37 °C. After incubation, the cells were washed with ice-cold phosphate-buffered saline and 
resuspended in 80 µl lysis buffer (1% Triton X-100, 50 mM Tris-HCl [pH 8.0], 100 mM 
NaCl) containing several inhibitors (1 µg of antipain per ml, 2 µg of benzamidine per ml, 1 
µg of leupeptin per ml, 1 µg of chymostatin per ml, 1 µg of pepstatin A per ml, 1 mM 
phenylmethylsulfonyl fluoride). After addition of 80 ml 2x sample buffer (final 
concentrations of 2% SDS, 2% β-mercaptoethanol, and 10% glycerol in 300 mM Tris-Cl 
pH 6.8), the lysates were boiled for 2 min. Samples were run on a 10% polyacrylamide 
minigel for 1 h at 150 V and blotted for 2 h (50 V) on a 0.2-µm-pore-size polyvinylidene 
difluoride (PVDF) membrane at 4 °C. The PVDF membrane was blocked with 0.5% 
Tween-20 in PBS for 1 h at room temperature and subsequently incubated for 1 h with the 
ERK 1/2 or p38 MAPK phosphospecific rabbit antibodies diluted 1:2,000 in blocking 
buffer or with the PKC mouse antibody diluted 1:2,000. After being washed six times with 
PBS/0.5% Tween-20 for 3 min, the PVDF membrane was incubated at room temperature 
for 2 h with goat anti-rabbit-peroxidase conjugate (1:8,000 in blocking buffer) or with goat 
anti-mouse-peroxidase conjugate. The PVDF filter was again washed six times with 
PBS/0.5% Tween-20 and then twice with PBS for 5 min. Thereafter, proteins were 
visualized with enhanced chemiluminescence on film (Kodak X-OMAT LS). 
 
TNF-α ELISA 
Macrophages were grown in teflon flasks for six days after which they were seeded 
in a 48-well plate (4 x 105 / well). Next day cells were preincubated with specific enzyme 
inhibitors for 30 min after which they were incubated with the same inhibitors together with 
10 µM Aβ(1-42) at 37 °C in a humidified atmosphere of 5% CO2 / 95% air. After 5 hours a 
sample of the supernatant was taken and the TNF-α concentration was quantified with an 
ELISA. In short, TNF-α was captured by monoclonal anti-human TNF-α antibody and 
detected with a biotinylated anti-human TNF-α antibody according to the manufacturer’s 
instructions (Pelikine compact human TNF-α ELISA kit, Central Laboratory of the 
Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands). 
 
Superoxide anion production 
Superoxide production was measured as lucigenin-enhanced chemiluminescence 
(33). Briefly, cells were transferred to polystyrene vials (2 x 105 / vial), placed into a 
luminometer (Packard Instruments, Belgium) and incubated for 30 min at 37 °C in HBSS 
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containing 250 nM bis-N-methylacridinum (Lucigenin) to assess the spontaneous release of 
superoxide. Subsequently, cells were preincubated with specific enzyme inhibitors for 30 
min after which 10 µM Aβ(1-42) was added and chemiluminescence (expressed as 
millivolts, mV) was monitored for 30 min. 
 
Results 
 
To resolve the intracellular pathways in Aβ-stimulated MDMs leading to the 
production of TNF-α and superoxide anions, the stimulation of ERK 1/2, p38 MAPK and 
PKC in macrophages stimulated with Aβ(1-42) was investigated. First primary human 
macrophages stimulated for 2, 5, 10, 20 and 40 min with 10 µM Aβ(1-42) were stained on 
Western blot for phosphorylated ERK 1/2. Results showed an increased ERK 1/2 activity 
after 2 min (Fig. 1A). The decline of ERK 1/2 activity started 5 min after stimulation.  
 
 
Figure 1 
Aβ(1-42) specifically activates ERK 1/2 in primary human macrophages. Cells were incubated with 10 
µM Aβ(1-42) for 2, 5, 10, 20 and 40 min. Aliquotes of the cell lysates were resolved by SDS-PAGE, Western 
blotted and visualized by chemiluminescence. (A) anti-phospho-ERK rabbit antibodies show an increase in 
activated ERK 1/2 after 2 min incubation with Aβ(1-42) compared to control cells. (B) anti-phospho-p38 rabbit 
antibodies show no stimulation of p38 MAPK activity after incubation with Aβ(1-42). (C) Mouse antiserum 
containing antibodies against PKC show no increase in PKC after stimulation with Aβ(1-42). We isolated 
monocytes from 4 different donors and consequently performed a whole cell extraction on Aβ-stimulated 
macrophages after 7 days. Each whole cell extract was blotted and stained at least two times. 
 
Figure 1B indicates that Aβ(1-42) could not activate p38 MAPK beyond the 
background activity in control cells (Fig 1B, lane 1). There seems to be a slight increase in 
p38 activity after 40 min. However, this effect was not reproducible. All extracts showed a 
constant p38 activity. Aβ(1-42)-stimulated macrophages showed no PKC activity on 
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Western blots (Fig 1C). We isolated monocytes from 4 different donors and consequently 
performed a whole cell extraction on Aβ-stimulated macrophages after 7 days. Each whole 
cell extract was blotted and stained at least two times. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
Inhibition of the Aβ(1-42)-induced superoxide anion production in primary human macrophages. Cells 
were preincubated with inhibitors for 30 min after which they were exposed to buffer (open circle) or to 10 µM 
Aβ(1-42) (closed circle). Superoxide anion production was inhibited with 10 (open square), 1 (open triangle) and 
0.1 (closed triangle) µM staurosporine (A), 100 (open square), 33 (open triangle) and 10 (closed triangle) nM 
bisindolylmaleide (B), 50 (open square), 25 (open triangle) and 12.5 (closed triangle) µM PD098059 (C) and 50 
(open square), 25 (open triangle) and 12.5 (closed triangle) µM SB202190 (D). 
 
Macrophages, isolated from several donors, showed a consequent increase (~ 3.4 
fold) of superoxide anion production within the first 6 min after exposure to 10 µM Aβ(1-
42) (Fig. 2A-D). To determine whether ERK 1/2, p38 MAPK and PKC are involved in the 
activation of the NADPH-complex and consequent release of superoxide anions, 
macrophages were incubated with specific enzyme inhibitors. Incubation with 
staurosporine revealed a partial inhibition of superoxide anion production at a concentration 
of 100 nM and complete inhibition at concentrations of 1 µM and higher (Fig. 2A). 
Incubation with bisindolylmaleimide, a specific PKC inhibitor, showed a partial inhibition 
at 10 and 33 nM and a nearly complete inhibition at 100 nM (Fig. 2B). Complete inhibition 
was seen at 500 nM and higher concentrations (data not shown). To determine whether 
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ERK 1/2 and the p38 MAPK signal transduction pathways are involved in the superoxide 
anion production, macrophages were incubated with PD098059 as a specific inhibitor for 
ERK 1/2 and SB202190 as a specific inhibitor for p38 MAPK. Incubation with 12.5, 25 and 
50 µM PD098059 revealed a partial inhibition of the superoxide anion production (Fig. 
2C). Treatment with SB202190 at 12.5, 25 and 50 µM also resulted in a partially inhibited 
superoxide anion production (Fig. 2D). These results suggest that the PKC, ERK 1/2 and 
p38 MAPK signal transduction pathways are involved in superoxide anion production of 
Aβ(1-42)-induced macrophages.  
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Figure 3 
Inhibition of the Aβ(1-42)-induced TNF-α production in primary human macrophages. Cells were 
preincubated with 10 µM staurosporine (stauro), 500 nM bisindolylmaleimide (bis), 50 µM pd098059 (pd) and 
50 µM sb202190 (sb) after which they were incubated with 10 µM Aβ(1-42) together with these inhibitors for 5 
hours. Supernatant samples were taken and TNF-α levels were quantified. Results are representative of three 
independent experiments (* p<0.05 compared to unstimulated cells, ** p<0.05 compared to Aβ(1-42)-stimulated 
cells). 
 
Macrophages stimulated with 10 µM Aβ(1-42) also revealed a 4.3 fold (p<0.05) 
increase in TNF-α production (Fig. 3). To check whether PKC is involved in Aβ-induced 
TNF-α production, cells were incubated with staurosporine as well as bisindolylmaleimide. 
Incubating macrophages with 50 µM staurosporine revealed a complete block of the TNF-α 
production (p<0.01), whereas treatment with 500 nM bisindolylmaleimide showed no 
significant decrease in TNF-α production. To investigate the involvement of ERK 1/2 in 
the Aβ-stimulated TNF-α production cells were incubated with 50 µM PD098059. As 
shown in Fig. 3, PD098059 resulted in a complete inhibition of TNF-α production 
(p<0.02).  
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Figure 4 
Mechanism of macrophage activation by Aβ leading to the release of pro-inflammatory superoxide anions 
and TNF-α. A schematic is shown indicating the relationships between Aβ on one hand and superoxide anion and 
TNF-α on the other hand. Aβ can activate macrophages (1) which triggers Protein Kinase C (2) and subsequently 
stimulates NADPH (3) to release superoxide anions. Aβ stimulation also induces ERK 1/2 and p38 MAPK (4). 
ERK 1/2 activation induces TNF-α production (5) and partially induces NADPH activity (6). P38 activation only 
induces NADPH activation (7). Protein kinase C is suggested to activate ERK 1/2 as outlined in the discussion (8). 
 
Macrophages were incubated with 50 µM SB202190 to check whether p38 MAPK 
is involved in TNF-α production. The results clearly indicate that there is no significant 
decrease of TNF-α (Fig 2). All together, these results indicate that although staurosporine 
inhibits TNF-α production PKC seems not involved in the Aβ stimulated TNF-α 
production due to the fact that bisindolylmaleimide does not show any inhibition. The ERK 
1/2 pathway seems involved in the Aβ-stimulated TNF-α production in contrast to p38 
MAPK pathway (Fig. 4).  
 
Discussion 
 
Neuritic plaques in brains of people suffering from AD are found to be surrounded 
by microglia. These microglia are normally in a resting state but they can be activated by 
numerous signals from their surroundings. Depending on the signal, these microglia can 
then produce a number of pro-inflammatory products. In AD these microglial cells are 
activated and are thought to produce a number of pro-inflammatory products. By doing so 
these microglia are thought to stimulate and enhance the neuronal damage and by activating 
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surrounding microglia are thought to continue the inflammatory process. In the study 
presented in this paper we have tried to partially unravel the intracellular pathways 
activated in microglia as a response to Aβ, leading to the production of the pro-
inflammatory products TNF-α and superoxide anions. Our results show that upon Aβ(1-42) 
stimulation macrophages produce TNF-α. Using specific inhibitors it was shown results 
show that ERK 1/2, and not p38 MAPK and PKC, plays an important role in the production 
of TNF-α. Western blot analysis confirms the ability of Aβ to stimulate the activation of 
ERK 1/2. Regarding the production of superoxide anions, the situation is different. 
Bisindolylmaleimide can completely inhibit the superoxide anion production indicating an 
important role for PKC. We could however not detect an activation of PKC on Western 
blot. Furthermore, inhibiting properties of PD098059 and SB202190 indicate participation 
of ERK 1/2 and p38 MAPK in the signal transduction pathway leading to superoxide anion 
production. However, using these inhibitors the superoxide anion production could not be 
blocked completely, indicating a possible existence of multiple pathways. 
Despite extensive research over the last years, the precise pathways following Aβ 
stimulation are not yet fully understood. Differences in the source and in the use of Aβ and 
differences in the cells used as a model for human microglia often results in different 
outcomes. Studies performed with rat microglia and THP-1 monocytes stimulated with 
Aβ(1-40) showed an activation of ERK 1/2 as well as p38 MAPK (22). Studies by Pyo et 
al. using Aβ(25-35)-stimulated rat microglia showed a correlation between ERK 1/2 and 
p38 MAPK and TNF-α production (34), in contrast to results presented in this paper. In our 
study Aβ(1-42) and human macrophages were used in contrast to Aβ(25-35) and rat 
microglia that were used by Pyo et al.  
Although the signal transduction pathways of the Aβ-induced TNF-α production in 
mononuclear cells have been studied by several investigators, to our knowledge no studies 
have been performed on the Aβ-induced signal transduction pathways that lead to 
superoxide anion production. A study by Yagisawa et al. on fMLP-stimulated human 
monocytes showed a partial inhibition of the superoxide release by PD098059 or SB202190 
(35). In neutrophils stimulated by fMLP or PMA a relation between NADPH oxidase and 
p38 MAPK has also been demonstrated (36). Using SB202190 as a specific inhibitor, our 
results show p38 MAPK as an intermediate for superoxide anion production and show p38 
MAPK not to be involved in TNF-α production. Looking at the Western blots we could not 
detect Aβ(1-42) to be able to activate p38 MAPK beyond the level found in control cells. 
However, because of the use of a specific inhibitor we hypothesize p38 MAPK to be an 
intermediate in the signal transduction pathway leading to the production of superoxide 
anions, independent of stimulation with Aβ. Because the pathway between Aβ located near 
the cell membrane and the activation of p38 MAPK is not yet understood, further 
investigation is necessary to define the role of p38 MAPK. 
This paper shows results indicating that PKC is not involved in the TNF-α 
production but seems to be important in the superoxide anion production. Using a 
monoclonal antibody to stain Western blots we could not detect an activation of PKC. 
Because of the many function of PKC in the cell it is possible that the amount of PKC 
activated in the cell is very low. Moreover our results show that the superoxide anion 
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production could nearly completely be inhibited using only 100 nM bisindolylmaleimide. It 
is possible that because of this low amount of PKC activated we could not detect its activity 
on Western blot. Several other studies have indicated that PKC might be involved in the 
pathways following Aβ treatment. A minor induction of TNF-α, which could be inhibited 
by PKC inhibitor H-7, was found in Aβ(1-40)-induced THP-1 monocytes (11). Also Siedlar 
et al. found that upon stimulation of monocytes with colorectal cancer cells, PKC activation 
is involved (37). It has also been shown that stimulation with Aβ(25-35) and the consequent 
chemotaxis of microglial cells also required PKC as an intracellular intermediate (38). 
Recently Combs et al. showed that upon stimulation with fibrillar Aβ PKC activity is 
required for protein tyrosine phosphorylation (23). Whether there is a link between PKC 
and ERK 1/2 is still not clear, as shown in Fig. 4. Combs et al. found ERK 1/2 being a 
downstream event of PKC activation (23). Haring et al. however found ERK 1/2 and PKC 
to be operating in parallel in the secretion of the soluble form of amyloid precursor protein 
in PC12 cells (39). Because of the complete inhibition of PKC and the partial inhibition of 
ERK 1/2 in the superoxide anion production, our results suggest a link (Fig. 4). It seems 
however be possible to activate ERK 1/2 independent of PKC since our results indicate a 
difference between bisindolylmaleimide and staurosporine in Aβ-stimulated TNF-α 
production. Moreover, staurosporine not only inhibits PKC but also inhibits PKA, PKG and 
CaM. 
The capabilities of staurosporine to inhibit various kinases together with the 
different results of bisindolylmaleimide and staurosporine suggest that other enzymes are 
involved in the Aβ-stimulated production of TNF-α. Other studies showed that inhibition 
of PKA did not change TNF-α levels in monocytes (37,40). Also Wood et al. showed that 
in microglia PKG seems not to be involved in LPS-stimulated TNF-α release (41). 
Furthermore, Mattsson et al. found CaM kinase to be involved in the LPS-stimulated 
induction of TNF-α in human monocytes (42). All together these data suggest that nor 
PKC, nor PKA or PKG are likely to be involved in the Aβ(1-42)-induced TNF-α 
production and that CaM might be responsible. 
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Abstract 
 
In Alzheimer’s disease neuritic amyloid-β plaques together with surrounding 
activated microglia and astrocytes are thought to play an important role in the inflammatory 
events leading to neurodegeneration. Studies have indicated that amyloid-β can be direct 
neurotoxic and, by activating these glial cells to produce oxygen radicals and 
pro-inflammatory cytokines. This report shows that, using primary human 
monocyte-derived macrophages as model cells for microglia, amyloid-β(1-42) stimulate 
these macrophages to the production of superoxide anions and TNF-α. In contrast, 
astrocytes do not produce both inflammatory mediators when stimulated with 
amyloid-β(1-42). In cocultures with astrocytes and amyloid-β(1-42)-stimulated 
macrophages decreased levels of both superoxide anion and TNF-α were detected. These 
decreased levels of potential neurotoxins were due to binding of amyloid-β(1-42) to 
astrocytes since FACSscan analysis demonstrated binding of FITC-labeled 
amyloid-β(1-42) to astrocytoma cells and pretreatment of astrocytes with amyloid-β(1-16) 
prevented the decrease of superoxide anion in cocultures of human astrocytes and 
amyloid-β(1-42)-stimulated macrophages. In order to elucidate an intracellular pathway 
involved in TNF-α secretion, the activation state of NF-κB was investigated in 
macrophages and astrocytoma cells after amyloid-β(1-42) treatment. Interestingly, while 
activation of NF-κB could not be detected in amyloid-β-stimulated macrophages it was 
readily detected in astrocytoma cells. These results not only demonstrate that amyloid-β 
stimulation of astrocytes and macrophages result in different intracellular pathway 
activation but also indicate that astrocytes attenuate the immune response of macrophages 
to amyloid-β(1-42) by interfering with amyloid-β(1-42) binding to macrophages. 
 
Introduction 
 
Alzheimer’s disease (AD) is the most common cause of progressive dementia and a 
neurodegenerative disorder, which despite scientific progress in recent years is still a 
disease of unknown etiology. One pathological hallmark of AD is the presence of neuritic 
plaques in the cortical gray matter (1). These extracellular depositions are mainly composed 
of aggregated amyloid-β (Aβ) peptides and are surrounded by dystrophic neurites and glial 
cells. The Aβ peptide is derived through changes in the processing of the amyloid-β 
precursor protein (APP) and according to the ‘amyloid cascade hypothesis’ these changes 
are central to the disease process (2). Aβ is a 4 kDa peptide of 39-43 amino acids (3,4) and 
studies with synthetic Aβ show that it can act as a potent and direct neurotoxic agent (5-7).  
There is however an increasing amount of evidence that Aβ can be indirect 
neurotoxic by activating surrounding glial cells. Neuritic plaques, but not diffuse plaques, 
are reported to be surrounded by microglia (8-11). Since microglia are able to produce 
cytokines as well as chemotactic and neurotoxic factors a lot of research has focused on the 
ability of Aβ to induce these events in microglia. Recent studies show that Aβ is able to 
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trigger the generation of reactive oxygen species (ROS) in rat microglia and THP-1 
monocytes (12-14). Excessive release of ROS not only leads to oxidative stress but may 
also potentiate the inflammatory response, e.g. by triggering redox-sensitive expression of 
various inflammatory genes (5,15,16). Aβ has also been shown to induce interleukin-1β 
(IL-1β), tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-β) and 
neurotrophic molecules like nerve growth factor (NGF) and basic fibroblast growth factor 
(bFGF) in THP-1 monocytes (17-19).  
Aβ, cytokines and ROS released by microglia cannot only be direct neurotoxic, they 
may also activate surrounding astrocytes. Astrocytes are associated with many, but not all 
senile plaques. They are most closely associated with plaques with a dense amyloid core 
and an attendant microglial reaction (20-22). In vitro studies show that Aβ can stimulate the 
production of IL-1β and NO in rat astrocytes (23,24). It has also been shown that activity of 
iNOS in microglial cells is inhibited by the presence of astroglial cells, probably involving 
TGF-β (25). In addition, astrocytes have been shown to inhibit phagocytic properties of 
microglial cells (26). 
Although extensive research has shown that microglia as well as astrocytes are 
involved in the inflammatory process occurring around neuritic plaques it remains unclear 
how Aβ activates these microglia and astrocytes. Research of the microglial signal 
transduction pathways mediating the neurotoxic response of Aβ has revealed the mitogen-
activated protein kinase (MAPK) superfamily members ERK1/2 and p38 MAPK as 
important mediators (27,28). Besides, an increasing amount of evidence shows that the 
transcription factor nuclear factor-κB (NF-κB) can be stimulated by Aβ in neurons 
(5,16,29) and by Aβ(25-35) in microglia (30,31). Upregulation of ERK1/2 and p38 MAPK 
can lead to the activation of numerous transcription factors in their turn leading to the 
activation of cytokines and neurotrophic factors. Activation of NF-κB can lead to the 
transcription of genes expressing TNF-α, IL-1, IL-6, monocyte chemoattractant protein-1 
(MCP-1) and nitric oxide (NO) synthase (reviewed in (15)).  
To further explore the microglia and astrocyte-mediated inflammatory pathways, in 
the present study the capability of Aβ to induce NF-κB, TNF-α and superoxide anions in 
microglia and astrocytes was investigated. In addition the production of these pro-
inflammatory molecules was also investigated in cocultures of these cells in order to reveal 
the intercellular relationship regarding Aβ-induced central nervous system (CNS) 
inflammation. 
 
Materials and Methods 
 
Cells 
Monocytes were derived from peripheral blood mononuclear cells by Ficoll-Paque 
(Pharmacia Biotech, Sweden) density gradients and purified by centrifugal elutriation as 
described previously (32). Cells were seeded at a concentration of 2 x 106 cells / ml in 
Teflon Erlenmeyer flasks (Nalgene, USA) and grown as suspension at 37 °C in a 
humidified atmosphere of 5% CO2 / 95% air. Culture medium was composed of Iscove’s 
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modified Dulbecco’s medium (Gibco Life Technologies, The Netherlands) supplemented 
with 10% (v/v) heat-inactivated human AB serum, 2 mM L-glutamine, 19 mM sodium 
bicarbonate, 10 µg/ml gentamicin and 0.5 µg/ml ciprofloxacin. After 7 days, monocyte-
derived macrophages (MDMs) were harvested from the flasks, washed with Hanks’ 
balanced salt solution (HBSS) and used for the experiments. 
The human astrocytoma cell line U-373 MG was grown in a humidified atmosphere 
of 5% CO2 / 95% air in Dulbecco’s modified eagle medium / Nutrient mixture Ham F-10 
(Gibco Life Technologies), 1:1, supplemented with 10% (v/v) fetal calf serum, 10 IU / ml 
penicillin, 10 IU / ml streptomycin and 1.2 mM L-glutamine.  
Primary human adult astrocytes were kindly provided by Dr. C.J.A. de Groot and 
were cultured as described earlier (33). In short, cells were seeded into poly-L-lysine (PLL; 
15 µg/ml; Sigma Chemical Co., The Netherlands) coated 80 cm2 flasks at a density of 2 x 
104 cells/ml in Dulbecco’s modified eagle medium / Nutrient mixture Ham F-10, 1:1, 
supplemented with 10% (v/v) fetal calf serum, 10 IU / ml penicillin, 10 IU / ml 
streptomycin. For each new passage confluent cultures of astrocytes were harvested using 
0.25% trypsin in 0.02% EDTA. 
 
Amyloid-β peptides 
The synthetic Aβ peptides Aβ(1-42) and Aβ(1-16) (Bachem AG, Switzerland), 
prepared as stock solutions in sterile water at a concentration of 500 µM, were stored at –20 
ºC. FITC-labeled Aβ(1-42) was prepared by incubating Aβ(1-42) at a concentration of 10 
mg/ml with 0.1 mg/ml FITC in PBS (pH = 7.4) for 1 h at 22 ºC. Subsequently, using a 1 
kDa Spectra/Pordialyzation membrane, Aβ(1-42)-FITC was dialyzed overnight against 
PBS to remove unbound FITC, diluted to a concentration of 220 mM and stored at –20 ºC. 
 
Preparation of nuclear extracts 
MDMs or astrocytoma cells (1 x 106 cells / sample) were incubated with 10 µM 
Aβ(1-42) for 1 h at room temperature. Hereafter nuclear extracts were prepared as 
described previously (34). Briefly, cells were pelleted, washed with TRIS-buffered saline 
and resuspended in an ice-cold hypotonic buffer. Cells were allowed to swell on ice for 15 
min, after which a solution of Nonidet NP-40 was added. After centrifugation the pellet was 
vigorously shacked in an ice-cold hypertonic buffer. Nuclear extracts were centrifuged and 
the supernatant was aliquoted and stored at –70 °C until use. 
P50 and p65 positive controls were obtained as described before (35). In short, 
COS-1 cells were grown in 10 cm dishes and transfected with 20 µg of expression plasmid 
by the calcium-phosphate precipitation method. Cells were harvested 48 h post-transfection 
after which whole cells extracts were made. Extracts were stored at –70 °C until use. 
 
Electrophoretic mobility shift assay (EMSA) 
Nuclear extracts (5 µg protein per sample) were incubated with a double stranded 
32P-labeled probe containing the NF-κB binding motif from the HIV-long terminal repeat 
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(HIV-LTR, 5’-agcttcagaGGGGACTTTCCgagagg-3’). Incubation was carried out at room 
temperature for 30 min in 20 µl (total volume) of 10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 
5% glycerol, 1 mM DTT, 2 µg poly(dI-dC), 1 µg BSA, 100 mM NaCl and 1 ng probe. 
Hereafter, samples were loaded on a 5% polyacrylamide gel and run until free probe was at 
the end of the gel. Films were exposed to vacuum dried gels at –70 °C in cassettes 
containing intensifying screens. 
 
TNF-α ELISA 
Macrophages were grown in teflon flasks for six days after which they were seeded 
in a 48-well plate (4 x 105 / well). For coculture experiments astrocytes were grown in 24-
well plates. When confluent an equal amount of macrophages was added. Cells then were 
incubated with 10 µM Aβ(1-42) for indicated times at 37 °C in a humidified atmosphere of 
5% CO2 / 95% air. TNF-α concentration in the supernatant was quantified with an enzyme-
linked immunosorbent assay (ELISA). In short, TNF-α was captured by monoclonal anti-
human TNF-α antibody and detected with a biotinylated anti-human TNF-α antibody 
according to the manufacturer’s instructions (Pelikine compact human TNF-a ELISA kit, 
Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, 
The Netherlands) 
 
Superoxide anion production 
Superoxide production was measured as lucigenin-enhanced chemiluminescence 
(36). Briefly, cells were transferred to polystyrene vials (2 x 105 / vial), placed into a 
luminometer (Packard Instruments, Belgium) and incubated for 30 min at 37 °C in HBSS 
containing 250 nM bis-N-methylacridinum (Lucigenin; Sigma Chemical Co., The 
Netherlands) to assess the spontaneous release of superoxide. Subsequently, Aβ peptides 
were added and chemoluminescence (expressed as millivolts, mV) was monitored for 30 
min. 
 
Flow cytometry 
For Aβ(1-42)-FITC binding studies, 2 x 105 cells were incubated at 37 ºC with 
HBSS containing different concentrations Aβ(1-42)-FITC. In addition, 2 x 105 cells were 
first preincubated with 50 µM unlabeled Aβ(1-16) at 37 ºC for 30 min after which cells 
were washed with HBSS and incubated with 10 µM Aβ(1-42)-FITC. After 30 min, cells 
were washed with HBSS and fixed for 15 min with PBS containing 2% paraformaldehyde. 
Thereafter, flow cytometry analysis was performed by analyzing 10000 cells per 
experimental condition on a FACSscan flow cytometer (Becton Dickson and Co., USA) 
equipped with a computer-assisted data analysis system. 
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Statistical analysis 
The non-parametric Wilcoxon signed-rank test for two related samples was used to 
compare TNF-α secretion in unstimulated and Aβ(1-42)-stimulated  macrophages (Fig 1). 
The Wilcoxon test was also used to compare TNF-α secretion in Aβ(1-42)-stimulated 
macrophages and Aβ(1-42)-stimulated macrophages cocultured with astrocytoma cells (Fig 
2A) and primary human adult astrocytes (Fig 2B). Reported p-values are two-sided. All 
statistical analyses were performed using SPSS for Windows (8.0.0). 
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Figure 1. 
TNF-α secretion by Aβ(1-42)-stimulated macrophages. Unstimulated and Aβ(1-42)-stimulated 
macrophages were incubated for 4, 8, 16 and 24 hours after which supernatant samples were taken and TNF-α 
levels were quantified. Each bar represents mean ± SEM from seven independent experiments each using cells 
from different donors. Asterisks indicate statistically significant differences in TNF-α secretion from stimulated 
macrophages compared to unstimulated macrophages. 
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Figure 2. 
TNF-α secretion by Aβ(1-42)-stimulated macrophages cocultured with (A) human U-373 astrocytoma 
cells and (B) primary human adult astrocytes. Unstimulated and 10 µM Aβ(1-42)-stimulated macrophages were 
cocultured for 6 hours with astrocytes after which supernatant-samples were taken and TNF-α levels were 
quantified. Each bar represents mean ± SEM from eight independent experiments each using macrophages from 
different donors. Asterisks indicate statistically significant difference in TNF-α secretion from stimulated 
macrophages compared to unstimulated macrophages. Double asterisks indicate statistically significant difference 
in TNF-α secretion from Aβ(1-42)-stimulated macrophages cocultured with (A) human U-373 astrocytoma cells 
and (B) primary human adult astrocytes compared to Aβ(1-42)-stimulated macrophages. 
 
 
Chapter 4 
 44 
Results 
 
TNF-α secretion by Aβ(1-42)-stimulated primary human macrophages is attenuated by 
astrocytes 
To investigate whether Aβ(1-42) is capable of inducing primary human 
macrophages to produce pro-inflammatory cytokines and thus being indirectly neurotoxic 
MDMs were stimulated with 10 µM Aβ(1-42) for 4, 8, 16 and 24 hours and TNF-α 
concentrations were measured in the supernatant. As indicated in Figure 1 there is a 
significant (p=0.018) increase in TNF-α secretion at 4, 8, 16 and 24 hours as compared to 
unstimulated control cells. Maximum TNF-α secretion was measured after 24 hours of 
incubation. Our results are supported by reports published earlier by Fiala et al. (37) and 
Klegeris et al. (19) where TNF-α secretion was measured in human monocytes and human 
monocytic THP-1 cells respectively. Figure 2A shows TNF-α levels of human 
macrophages and human astrocytoma cells incubated with 10 µM Aβ(1-42) for 6 hours, 
Figure 2B shows TNF-α levels of human macrophages and primary human adult astrocytes 
incubated with 10 µM Aβ(1-42) for 6 hours. Whereas macrophages can produce significant 
levels of TNF-α, astrocytoma cells and primary human adult astrocytes do not when 
stimulated with Aβ(1-42). When stimulated macrophages are cocultured with either 
unstimulated astrocytoma cells or unstimulated primary human adult astrocytes there is a 
significant decrease in TNF-α secretion by these macrophages compared to Aβ(1-42)-
stimulated macrophages (p=0.028 and p=0.032 respectively). 
Theoretically, several mechanisms may account for the observed decrease in TNF-
α levels in the macrophage-astrocyte cocultures. Among them are the ability of astrocytes 
to bind Aβ(1-42) and in such a way interfere with Aβ(1-42) activation of macrophages, the 
ability to bind TNF-α and in such way decrease the levels of TNF-α in the supernatant, the 
ability to produce macrophage deactivating molecules such as IL-10 and TGF-β or other 
molecules such as soluble TNF-α receptor. To study the binding of Aβ(1-42) to human 
astrocytes, astrocytoma cells were incubated with different concentrations of FITC-labeled 
Aβ(1-42). Figure 3 shows that increasing concentrations of FITC-labeled Aβ(1-42) results 
in an increase in fluorescence  intensity of the cells. Moreover, preincubating astrocytoma 
cells with 50 µM unlabeled Aβ(1-16) for 30 min before incubation with 10 µM Aβ(1-42)-
FITC shows a decrease in fluorescence intensity of the cells (Fig 3E). These data suggest 
that astrocyte binding of Aβ(1-42) interferes with Aβ(1-42) activation of macrophages. 
 
Superoxide anion production of Aβ(1-42)-stimulated primary human macrophages is 
attenuated by astrocytes 
In order to study the effect of Aβ(1-42) on superoxide anion production by human 
macrophages, astrocytoma cells, primary human adult astrocytes and combined 
macrophage-astrocytoma and macrophage-primary human adult astrocyte cultures were 
placed into a luminometer and stimulated with Aβ(1-42). Figure 4A shows that 
macrophages do produce superoxide anions, Figure 4B shows that astrocytoma cells do not 
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when stimulated with 10 µM Aβ(1-42). Figure 4E shows that primary human adult 
astrocytes also do not produce superoxide anions when stimulated with 10 µM Aβ(1-42). 
There was however a decrease in the respiratory burst of macrophages when cocultured 
with astrocytoma cells (Fig 4C) or human adult astrocytes (Fig 4F). To investigate this 
effect astrocytoma cells and human adult astrocytes were pre-incubated with 50 µM Aβ(1-
16) for 15 min, prior to the Aβ(1-42) incubation, thereby blocking the binding of Aβ(1-42) 
to these astrocytes (38). The results, shown in Figure 4C and 4F, show that the attenuation 
of the respiratory burst by astrocytoma cells and human adult astrocytes was neutralized 
concluding that binding of Aβ(1-42) to the astrocytes might interfere with Aβ(1-42) 
activation of macrophages which in turn might result in a decreased superoxide anion 
production. Primary human adult astrocytes incubated with 50 µM Aβ(1-16) alone did not 
show any superoxide anion production (data not shown) or TNF-α production (Fig 2B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 
Binding of FITC-labeled Aβ(1-42) to astrocytoma cells. Fluo
log of the fluorescence-intensity of Aβ(1-42)-FITC binding to astro
histograms of unlabeled (autofluorescence; solid line) and 10 (A), 5 (B)
labeled human astrocytoma cells (dotted line). In addition, astrocytom
Aβ(1-16) before incubation with FITC-labeled Aβ(1-42) (E).  Superim
(autofluorescence; solid line), 10 µM Aβ(1-42)-FITC (dotted line) and
unlabeled 50 µM Aβ(1-16) (broken line). Results are representative of 
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Figure 4. 
The effect of coincubation of human astrocytoma cells (A-C) with human macrophages on the Aβ(1-42)-
stimulated superoxide anion production and primary human adult astrocytes (D-F) with human macrophages on 
the Aβ(1-42)-stimulated superoxide anion production. (A) Macrophages are exposed to buffer or 10 µM Aβ(1-42), 
(B) astrocytoma cells are exposed to buffer or 10 µM Aβ(1-42). (C) To investigate the effect of astrocytes on the 
respiratory burst of macrophages, astrocytes were preincubated for 15 min with buffer or 50 µM Aβ(1-16) after 
which they were coincubated with macrophages and exposed to buffer or Aβ(1-42). Also macrophages alone were 
exposed to 10 µM Aβ(1-42). Experiment was repeated using primary human adult astrocytes. (D) Macrophages 
are exposed to buffer or 10 µM Aβ(1-42), (E) primary human adult astrocytes are exposed to buffer or 10 µM 
Aβ(1-42). (F) To investigate the effect of astrocytes on the respiratory burst of macrophages, human astrocytes 
were preincubated for 15 min with buffer or 50 µM Aβ(1-16) after which they were coincubated with 
macrophages and exposed Aβ(1-42). Also macrophages alone were exposed to 10 µM Aβ(1-42). Results are 
representative of five independent experiments each using macrophages from different donors. 
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Aβ(1-42)-induced NF-κB activity in human astrocytoma cells, human macrophages and 
cocultures their of 
To investigate the role of astrocytes in the inflammatory process occurring around 
neuritic plaques the activation state of NF-κB in Aβ(1-42)-stimulated human U-373 MG 
astrocytoma cells was characterized. Therefore cells were stimulated with 10 µM Aβ(1-42) 
for 3, 6, 12 and 24 hours (3, 12 and 24 hour data not shown). Maximal NF-κB stimulation 
was seen after 6 hours (Fig 5). Aβ(1-42) stimulation results in the appearance of band A 
(Fig 5: lane 4) when compared to unstimulated control cells (Fig 5: lane 3). To identify 
band A we performed a supershift by incubating nuclear extracts and 32P-labeled 
oligonucleotide probes together with an antibody against either the p50 or the p65 subunits 
of NF-κB (Fig 5: lanes 5 and 6 respectively). The appearance of bands S1 and S2 indicate 
that stimulation of astrocytes with Aβ(1-42) results in activation of the NF-κB heterodimer 
p50/p65.  
 
 
 
Figure 5. 
NF-κB stimulation in Aβ(1-42)-stimulated human U-373 astrocytoma cells. Nuclear extracts from 10 µM 
Aβ(1-42)-stimulated astrocytes were incubated with 32P-labeled NF-κB oligonucleotide probe for electrophoretic 
mobility shift assays. Lanes: 1, probe; 2, LPS stimulated astrocytoma cells; 3, unstimulated astrocytoma cells; 4, 
astrocytoma cells stimulated with 10 µM Aβ(1-42); 5-6, nuclear extracts of Aβ(1-42)-stimulated astrocytoma cells 
incubated with a monoclonal antibody against NF-κB p50 subunit (5) and p65 subunit (6); NF-κB p50/p65 is 
indicated by band A, S1 and S2 indicate supershifts of p50 and p65 respectively. Results are representative of 
three independent experiments. 
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Figure 6. 
NF-κB stimulation in Aβ(1-42)-stimulated human U-373 astrocytoma cells. Nuclear extracts from 10 µM 
Aβ(1-42)-stimulated astrocytes were incubated with 32P-labeled NF-κB oligonucleotide probe for electrophoretic 
mobility shift assays. Lanes: 1, probe; 2, unstimulated astrocytoma cells; 3, astrocytoma cells stimulated with 10 
µM Aβ(1-42); 4, nuclear extracts of Aβ(1-42)-stimulated astrocytoma cells incubated with a 50 fold excess of cold 
NF-κB probe; 5, p50/p50 positive control; 6, p50/p65 positive control. NF-κB p50/p65 is indicated by band A. 
Results are representative of two independent experiments. 
 
To confirm these results the same experiment was performed with a new batch of 
astrocytoma cells. Cells were stimulated with 10 µM Aβ(1-42) for 3, 6, 12 and 24 hours. 
Maximal NF-κB stimulation was seen after 6 hours (Fig 6). Aβ(1-42) stimulation resulted 
in the appearance of band A (Fig 6: lane 3) compared to unstimulated astrocytoma cells 
(Fig 6: lane 2). Nuclear extracts of Aβ(1-42)-stimulated astrocytoma cells incubated with a 
50 fold excess of cold NF-κB probe showed a disappearance of band A (Fig 6: lane 4). 
As shown in Figure 2B cocultures of primary human adult astrocytes and 
macrophages produced decreased TNF-α levels as compared to macrophages alone. 
Although the mechanism behind the decreased levels of TNF-α is related to Aβ(1-42)-
astrocyte binding, the astrocytes may also bind at least part of the TNF-α produced by 
macrophages. To investigate whether TNF-α can bind to astrocytes and stimulate NF-κB 
activation, human U-373 MG astrocytes were incubated for 6 hours with either 10 µM 
Aβ(1-42) (Fig 7: lane 2) or two different concentrations of TNF-α or 10 µM Aβ(1-42) 
together with two different concentrations of TNF-α. Band A in Figure 7 shows that 1000 
IU/ml TNF-α (lane 3) as well as 2000 IU/ml TNF-α (lane 4) compared to unstimulated 
astrocytes (lane 1) clearly stimulate p50/p65 NF-κB heterodimer. Costimulation of Aβ(1-
42) together with TNF-α significantly increases NF-κB in the astrocytes (lane 5 and 6). 
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Figure 7. 
NF-κB stimulation in U-373 astrocytoma cells costimulated with Aβ(1-42) and TNF-α. EMSA was 
performed with nuclear extracts of astrocytes stimulated with either 10 µM Aβ(1-42), 1000 / 2000 IU/ml TNF-α 
or a combination their of. Lanes: 1, unstimulated astrocytes; 2, Aβ(1-42)-stimulated astrocytes; 3-4, astrocytes 
stimulated with 1000 and 2000 IU/ml TNF-α; 5, astrocytes stimulated with Aβ(1-42) and 1000 IU/ml TNF-α; 6, 
astrocytes stimulated with Aβ(1-42) and 2000 IU/ml TNF-α; 7, p50/p50 positive control; 8, p50/p65 positive 
control. Band A represents p50/p65 NF-κB dimer. Results are representative of two independent experiments. 
 
We showed that Aβ(1-42) could induce superoxide anion production as well as 
TNF-α secretion in human macrophages. To investigate whether NF-κB can be activated 
by Aβ(1-42) in human macrophages we incubated MDMs with 10 µM Aβ(1-42) for 3,6,12 
and 24 hours. Figure 8 shows the 3 hour incubation of macrophages with Aβ(1-42). Aβ(1-
42) stimulation (lane 2) does not increase NF-κB activity as compared to unstimulated 
control cells (lane 1). 6, 12 and 24 hour incubation periods show the same results (data not 
shown). 
As shown in Figure 2B and 4B, cocultures of human astrocytes and Aβ(1-42)-
stimulated macrophages produced decreased TNF-α levels as well as superoxide anion 
levels compared to macrophages alone. Therefore, NF-κB activity in cocultures of Aβ(1-
42)-stimulated macrophages and astrocytoma cells was determined (data not shown). 
Results show no difference of NF-κB activity in cocultures compared to macrophages alone 
(data not shown). 
 
 
 
 
Chapter 4 
 50 
 
 
Figure 8. 
NF-κB activity in Aβ(1-42)-stimulated macrophages. Lanes: 1, unstimulated macrophages; 2, 10 µM 
Aβ(1-42)-stimulated macrophages; 3, nuclear extracts of Aβ(1-42)-stimulated macrophages incubated with a 50 
fold excess of cold NF-κB probe; 4, p50/p65 positive control. Band A represents NF-κB. Results are 
representative of three independent experiments. 
 
Discussion 
 
In recent years, it has become increasingly evident that both Aβ and microglial cells 
play a fundamental role in the pathogenesis of AD. Aβ is not only believed to be direct 
neurotoxic, by activating microglial cells Aβ might be indirect neurotoxic. Although 
various receptors are reported to bind Aβ as a ligand (39-41), a specific receptor for Aβ on 
macrophages has not been found yet. However, it is suggested that the 1-16 domain of the 
peptide is believed to be responsible for binding to the macrophage, thereby activating 
numerous intracellular signal transduction pathways leading to transcription and production 
of pro-inflammatory products (38,42,43). Induction of TNF-α has been shown in THP-1 
monocytic cells and in rat and murine microglial cells (19,44-46). The induction of 
monocytic activation has been achieved by many investigators using micromolar 
concentration of Aβ (28,37,45,47-50). Indeed, stimulation of THP-1 cells with nanomolar 
concentration did not result in monocytic activation as measured by the release of pro-
inflammatory products (51). This report shows that using primary human monocyte-derived 
macrophages as a model cell for microglia, activation of these macrophages by Aβ(1-42) 
not only resulted in the production of superoxide anions but also preceded the release of 
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TNF-α. Although TNF-α is reported to be neuroprotective under certain conditions (52), 
the ability of Aβ to induce the release of TNF-α and superoxide anions in macrophages and 
the capability of TNF-α and reactive oxygen species to amplify the inflammatory reaction 
by numerous mechanisms in surrounding microglia and astrocytes underscores the 
importance of understanding the underlying molecular mechanisms in an attempt to slow or 
prevent injury to the brain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. 
Proposed mechanism of intercellular pathways eventually leading to
activate macrophages (1) to produce either TNF-α (2) or superoxide anions (3).
(5) can activate astrocytes or can be direct neurotoxic (6 + 7). Aβ may also activ
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unique mechanism of activation, its role in cytoplasmic/nuclear signaling and its exquisite 
responsiveness to pathogenic stimulation of cells. Several studies reported a relationship 
between Aβ and NF-κB activity in neurons (5,16,29,53) and astrocytes (24). In microglia 
Bonaiuto et al. showed NF-κB activation upon Aβ-stimulation (29,30). In this study 
however, a N9 murine microglial cell line was used. This report shows that Aβ was not able 
to induce NF-κB in primary human macrophages, in contrast to LPS (data not shown). 
However, incubating human astrocytes with Aβ(1-42) not only shows binding of the 
peptide to the cells but also shows activation of NF-κB, more specific the heterodimer 
p50/p65. Because NF-κB is known to be able to stimulate the transcription of TNF-α it can 
be concluded that because macrophages but not astrocytes showed TNF-α secretion after 
stimulation with Aβ(1-42) the intracellular pathway following this Aβ(1-42) stimulation in 
macrophages is different than in astrocytes. Other studies however showed an increased 
TNF-α secretion upon induction with Aβ (54,55). In these studies rat astrocytes were used, 
in contrast to the primary human adult astrocytes used in this study. This contradiction 
indicates that there are species differences regarding Aβ-stimulated TNF-α production. 
Although the expression of TNF-α is under control of NF-κB additional cellular 
transcription factors are necessary for the induction of TNF-α expression (56). Indeed, in 
addition to the results presented in this paper, NF-κB activity is reported to be 
constitutively present in monocytes (57) and MDMs (58,59). In astrocytes other, inhibitory 
factors, seem responsible for not producing TNF-α as a consequence of Aβ-stimulated NF-
κB activity. Astrocytes do however produce TNF-α when stimulated with LPS and this 
production is strongly amplified in the presence of Aβ(25-35) while Aβ(25-35) alone does 
not show this effect (60).  
 
Besides Aβ(1-42)-mediated NF-κB activation, this report also showed that TNF-α 
could induce NF-κB. Moreover TNF-α in combination with Aβ(1-42) showed an even 
higher NF-κB activity. Because astrocytes do not produce proinflammatory TNF-α and 
superoxide anions when stimulated with Aβ, other mechanisms might follow the activation 
of NF-κB. Akama et al. showed that in astrocytes Aβ stimulation of nitric oxide production 
occurs through an NF-κB dependent mechanism (24). Another study showed that IL-1β and 
TNF-α-stimulated alpha 1-antichymotrypsin production in astrocytes occurs via NF-κB 
(61). Astrocytes are also reported to produce IL-6 and IL-8 after stimulation with Aβ (62). 
In addition, our results show a neuroprotective role for astrocytes regarding the amount of 
superoxide anion and TNF-α release by macrophages induced in the presence of Aβ (Fig 
9). Taken together, these results not only demonstrate that upon binding and activation of 
Aβ to astrocytes and macrophages different intracellular mechanisms are responsible for 
the inflammatory response but also indicates that the interaction between astrocytes and 
macrophages plays an important role in the growing inflammatory response eventually 
leading to neurodegeneration. 
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Abstract 
 
In recent years extensive research has revealed an insight into the mechanisms as 
thought to exist in brains of people suffering from Alzheimer’s disease. These mechanisms 
are eventually responsible for the loss of neurons. One of the pathological hallmarks in 
those brains is the neuritic plaque. These plaques are surrounded by microglia as well as 
astrocytes. Amyloid-beta together with the pro-inflammatory products released by these 
microglia and astrocytes are held responsible for the damage done. There are far more glial 
cells surrounding the plaque than located elsewhere in the brain. Chemotaxis might be 
responsible for attracting these cells towards the neuritic plaque. Using primary monocyte-
derived macrophages and primary adult astrocytes as a model, the production of the 
chemoattractant CC-chemokines MIP-1α, MIP-1β, MCP-1 and RANTES in the presence 
and absence of amyloid-beta 1-42, 1-40 or 42-1 was investigated. Within 6 hours amyloid-
beta (1-42) was able to stimulate the production, as measured by RT-PCR, of MIP-1α and 
MIP-1β mRNA in macrophages and MCP-1 in astrocytes. Cocultures showed in 
unstimulated as well as in amyloid-beta-stimulated cells an increase in MIP-1α, MIP-1β 
and MCP-1 mRNA. ELISAs of supernatant samples of macrophages and astrocytes 
stimulated for 24 hours also showed an increase in MIP-1α and MIP-1β in macrophages 
and MCP-1 in astrocytes. Cocultures, however, showed an increase in MIP-1α, MIP-1β and 
MCP-1 when stimulated and no increase when unstimulated. These results show that CC-
chemokines might play an important role in attracting glial cells to the neuritic plaque and 
therefore in the continuation of the inflammatory response. 
 
Introduction 
 
Alzheimer’s disease (AD) is the most abundant form of dementia. Brains of people 
suffering from AD are characterized by depositions composed of aggregated amyloid-beta 
(Aβ) proteins and several other molecules (reviewed in (1,2)). These depositions are 
reported to be enclosed by activated microglia (3) and astrocytes (4,5). The depositions and 
the glial cells in their turn are surrounded by degenerating neurons. In total this is called the 
neuritic plaque. In contrast to the diffuse plaque which is found both in normal and AD 
brains. There is less Aβ present in these diffuse plaques and Aβ is not as aggregated as in 
neuritic plaques. Moreover, these diffuse plaques are reported not to be surrounded by 
microglia and astrocytes and neurons surrounding these diffuse plaques are not 
degenerating. 
The cause of neuronal loss has not been fully determined yet. There are, however, 
strong suggestions that the Aβ protein can be direct neurotoxic and that surrounding 
microglia and astrocytes may play an important role in the inflammatory response. Studies 
have shown that Aβ stimulation of THP-1 monocytes, rat microglia and primary human 
macrophages results in the production of an array of pro-inflammatory molecules (6-16). 
There are also several studies reporting the ability of Aβ-stimulated monocytes and 
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macrophages to produce anti-inflammatory cytokines (17). Taken together, all these studies 
have shown the complexity of the situation as it exists in the neuritic plaque. There are 
numerous glial cells present around each plaque, each residing in its own micro-
environment and each capable of producing pro- and/or anti-inflammatory products. It is 
the balance of pro-inflammatory products and anti-inflammatory products that may be 
essential in the degenerative process. In AD it is eventually leading to the degeneration of 
the neurons surrounding the plaque. 
Influencing this balance may help in slowing the disease. Therefore a lot of effort 
has been put in understanding the intracellular pathways leading to the release of these pro-
inflammatory products. The group of Landreth has done extensive research on the early 
events after Aβ stimulation of the microglia (18-21). They showed the involvement of the 
tyrosine kinases Lyn and Syk and more downstream the activation of the MAPK family 
members ERK1 and ERK2 in the Aβ stimulation of monocytes and microglia. Akama et al. 
showed NF-κB to be important in the Aβ-stimulated NO release in astrocytes (22,23). 
Klegeris et al. showed protein kinase C (PKC) to be involved in the Aβ-stimulated tumor 
necrosis factor-alpha (TNF-α) release in THP-1 monocytes (8,24). These reports also show 
that using specific enzyme inhibitors these pathways can be blocked, resulting in a 
decreased production of the pro-inflammatory products. This in turn may lead to a 
decreased neurodegeneration. 
Diffuse plaques are not surrounded by microglia and astrocytes. This in contrast to 
neuritic plaques. The extensive research on the production of pro- and anti-inflammatory 
products concentrates on the latter. Another possibility of changing the balance between 
pro- and anti-inflammatory products is questioning the recruitment of the microglia and 
astrocytes towards the plaque. There are far more microglia and astrocytes concentrated 
around these plaques than located elsewhere in the brain. Little is known about the 
mechanism responsible for attracting so much glial cells. The research presented in this 
paper focuses on the involvement of proteins with chemotactic capabilities in recruiting 
these cells to the plaque. One group of chemotactic proteins are the chemokines. 
Chemokines constitute a superfamily of chemotactic cytokines and are produced by a wide 
variety of cells, including T-cells, monocytes, endothelial cells, microglia and astrocytes 
(25,26). In addition to their chemotactic effects in the immune system, chemokines 
modulate a number of biological responses, including enzyme secretion, cellular adhesion, 
cytotoxicity, tumor cell growth, degranulation and T-cell activation (27). This superfamily 
of about 40 members is divided into two major subfamilies on the basis of the structural 
conservation of two N-terminal cysteine residues. This division depends on the presence 
(CXC) or absence (CC) of an additional amino acid between the first two residues. Two 
other classes of chemokines have been described: lymphotactin (C) and fractalkine (CX3C). 
The former one lacks cysteine residues one and three of the typical chemokines structure 
(28) and the latter one exhibits three amino acids between the first two cysteines and is also 
the only membrane-bound chemokine through a mucin-like stalk (29). The chemokines 
mediate their effects via G protein-coupled receptors of the seven transmembrane domain 
rhodopsin-type superfamily (30,31). These receptors are named CXCR, CCR, CR and 
CX3CR respectively.  
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In many central nervous system (CNS) diseases such as multiple sclerosis (MS), 
brain trauma, infections, or focal ischemia, the blood-brain barrier is breached, and 
leukocyte infiltration is found at the lesion sites (32). In AD however, the blood-brain 
barrier is intact and no infiltration of inflammatory cells is present. Because of the continual 
inflammation in the AD brain, resident CNS cells have to be involved, and indeed many 
CNS cells are reported to be able to produce chemokines and express chemokine receptors 
(33,34). Regarding Aβ-induced chemokine production however, only a small number of 
papers have been published. The CC-chemokines MIP-1α and MCP-1 have been found to 
be produced by Aβ-stimulated monocytes after 48 h of cultivation (35). Also Aβ(25-35)-
stimulated U373 astrocytoma cells have been reported to have an increased MCP-1 
production and rat astrocytes stimulated with 50 µM Aβ(1-42) for 6 h have been found to 
produce MCP-1 and RANTES mRNA (36,37). In rat astrocytes, the CC-chemokines MIP-
1α, MIP-1β, MCP-1 and RANTES mRNA expression can also be induced by either IFN-γ 
or TNF-α. 
This paper shows the results of the mRNA production of the CC-chemokines MIP-
1α, MIP-1β, MCP-1 and RANTES by primary human monocyte-derived macrophages as a 
model for microglia cells, by primary adult astrocytes and by cocultured MDMs and 
astrocytes when stimulated by Aβ(1-42), Aβ(1-40) for 2, 4, 6 and 8 hours. Moreover, 
chemokine supernatant levels in cultured MDMs, astrocytes and cocultures thereof are 
determined. 
 
Materials and Methods 
 
Cells 
Monocytes were derived from peripheral blood mononuclear cells by Ficoll-Paque 
(Pharmacia Biotech, Sweden) density gradients and purified by centrifugal elutriation as 
described previously (38). Cells were seeded at a concentration of 2 x 106 cells / ml in 
Teflon Erlenmeyer flasks (Nalgene, USA) and grown as suspension at 37 °C in a 
humidified atmosphere of 5% CO2/95% air. Culture medium was composed of Iscove’s 
modified Dulbecco’s medium (Gibco Life Technologies, The Netherlands) supplemented 
with 10% (v/v) heat-inactivated human AB serum, 2 mM L-glutamine, 19 mM sodium 
bicarbonate, 10 µg/ml gentamicin and 0.5 µg/ml ciprofloxacin. After 7 days, monocyte-
derived macrophages (MDMs) were harvested from the flasks, washed with Hanks’ 
balanced salt solution (HBSS) and used for the experiments. 
Primary human adult astrocytes were kindly provided by Dr. C.J.A. de Groot and 
were cultured as described earlier (39). In short, cells were seeded into poly-L-lysine (PLL; 
15 µg/ml; Sigma Chemical Co., The Netherlands) coated 80 cm2 flasks at a density of 2 x 
104 cells/ml in Dulbecco’s modified eagle medium / Nutrient mixture Ham F-10, 1:1, 
supplemented with 10% (v/v) fetal calf serum, 10 IU / ml penicillin, 10 IU / ml 
streptomycin. For each new passage confluent cultures of astrocytes were harvested using 
0.25% trypsin in 0.02% EDTA. 
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Amyloid-β peptides 
Lyophilized synthetic Aβ(1-42) peptide was obtained from Genosphere 
Biotechnologies (Paris, France). Lyophilized synthetic Aβ(1-40) and Aβ(42-1) peptides 
were purchased from Bachem AG (Bubendorf, Switzerland). Peptides were initially 
dissolved at a concentration of 1 mM in sterile double-distilled pyrogen-free water, after 
which they were aliquoted and stored at –20 °C. 
 
RT-PCR detection of chemokines  
Macrophages and astrocytes and cocultures hereof were homogenized and lysed in 1 
ml TRIzol (Gibco Life Technologies, Gaithersburg, MD) according to the manufacturer’s 
guidelines. Total RNA was isolated and dissolved in diethylpyrocarbonate (DEPC)-treated 
water and 1 µg of RNA was used for the synthesis of complementary DNA. Subsequent 
PCR reactions were performed as described previously (38). For semi-quantification every 
primer pair was tested at different cycle numbers to determine the linear range. MDM 
GAPDH mRNA levels were measured at 23 cycles, whereas cDNA had to be subjected to 
25 cycles to be in the linear range to detect MIP-1α, MIP-1β, and MCP-1 and 35 cycles for 
RANTES. Astrocyte GAPDH mRNA levels were measured at 23 cycles, whereas MCP-1 
mRNA levels were quantified at 25 cycles. MIP-1α, MIP-1β and RANTES mRNA levels 
were not detectable in astrocytes. In cocultures of MDMs and astrocytes GAPDH mRNA 
levels were measured at 23 cycles. MIP-1α, MIP-1β and MCP-1 cDNA were subjected to 
25 cycles. RANTES mRNA could not be detected in cocultures. 
Aliquots of 5 µl of the biotinylated PCR product were semi-quantitatively analyzed 
using a fluorescent digoxigenin detection ELISA kit (Roche) according to manufacturer’s 
protocol as described previously (38). All data were normalized against GAPDH mRNA 
levels. The sequences of the primers and probes are depicted in Table I. 
 
Chemokine ELISA 
Macrophages were grown in teflon flasks for six days after which they were seeded 
in a 48-well plate. Astrocytes were grown in a poly-L-lysine coated 48-well plate. 
Cocultures of macrophages and astrocytes were grown in a poly-L-lysine coated 48-well 
plate. Next day, cells were stimulated with 10 µM Aβ-peptides for 6, 12, 24, 36 and 48 
hours after which supernatant samples were taken. MIP-1α, MIP-1β, MCP-1 and RANTES 
concentrations were quantified with a sandwich enzyme-linked immunosorbent assay 
(ELISA). In short, chemokines were captured by a specific monoclonal antibody according 
to the manufacturer’s instructions (R&D Systems Europe, Abingdon, United Kingdom). 
 
Statistical analysis 
In all experiments Student-t test was used to compare unstimulated or Aβ(42-1)-
stimulated macrophages, astrocytes or cocultures thereof and Aβ(1-42)-stimulated 
macrophages, astrocytes or cocultures thereof. Reported p-values are two-sided. 
 
Chapter 5 
 64 
Results 
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1β (p=0.025), both with a maximum at 4 hours. There is however no obvious induction of 
MCP-1 and there seems to be a trend in the induction of RANTES mRNA (p=0.110). 
Aβ(1-40)-stimulated MDMs showed, in contrast to the effect of Aβ(1-42), no induction of 
either MIP-1α, nor MIP-1β, MCP-1 or RANTES (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
MIP-1α (A), MIP-1β (B), MCP-1 (C) and RANTES (D) secretion by Aβ(42-1)-stimulated, Aβ(1-42)-
stimulated and Aβ(1-40)-stimulated MDMs. Cells were incubated for 6, 12, 24, 36 and 48 hours after which 
supernatant samples were taken and chemokine levels were quantified. 24 h time point is shown. Experiment was 
done twice. Asterisks indicate statistically significant differences in MIP-1α and MIP-1β supernatant levels 
compared to Aβ(42-1)-stimulated macrophages. 
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no obvious induction of MCP-1 or RANTES. Both Aβ(1-40) and Aβ(42-1) showed no 
stimulated expression of the mentioned chemokines. 
The data of the RT-PCR and the ELISA show that Aβ(1-42) activates the 
macrophage, leading to the production and expression of MIP-1α and MIP-1β. 
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taken and CC-chemokine levels were determined 24 h after stimulation. Figure 6 shows the 
MIP-1α (A), MIP-1β (B) and MCP-1 (C) supernatant levels. 
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Figure 6 
MIP-1α (A), MIP-1β (B) and MCP-1 (C) secretion by Aβ(42-1)-stimulated, Aβ(1-42)-stimulated and 
Aβ(1-40)-stimulated cocultures of MDMs and astrocytes. Cocultures were incubated for 6, 12, 24, 36 and 48 hours 
after which supernatant samples were taken and chemokine levels were quantified. 24 h time point is shown. 
 
Discussion 
 
Trying to dissolve possible sources of inflammation in AD, one can only take into 
account CNS resident cells. Neuritic plaques in AD are surrounded by activated microglia 
and astrocytes and a large amount of the literature on AD has shown the possibility of these 
glial cells to produce inflammatory products when stimulated with Aβ (For review see 
(40)). It seems to be very likely that these cells are involved in the continuation of the 
inflammatory response, eventually leading to neuronal damage. 
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Because of the amounts of microglia and astrocytes surrounding neuritic plaques, 
active chemotaxis might be responsible for attracting those cells. Microglia as well as 
astrocytes have been shown to have chemotactic capabilities to several factors (41-43). 
Microglia has been shown to be chemotactic towards Aβ(25-35) and MIP-1α, MIP-1β and 
MCP-1 (41,42) and astrocytes have been shown to migrate towards MIP-1α (43). Here we 
show that primary human monocytes-derived macrophages used as a model for microglia 
are able to produce and express CC-chemokines MIP-1α and MIP-1β. In addition, primary 
human adult astrocytes are capable of producing and expressing MCP-1. Coculturing 
MDMs and astrocytes revealed an increased mRNA production of MIP-1α, MIP-1β and 
MCP-1 in unstimulated as well as Aβ(1-42)-stimulated cells. ELISA’s showed increased 
supernatant levels of all three in Aβ-stimulated cocultures. 
Due to the limited availability of microglia studying the interactions of Aβ and 
microglia has proven to be a difficult task. Human adult microglia would be the ideal cell 
type to use as an in-vitro model in studying microglia-mediated inflammation. Because of 
the limited availability of these cells and the difficulty of maintaining these cells in culture, 
different cell types have been used instead. The human monocytic cell line THP-1 has often 
been used as a model for microglia. A recent paper of Szczepanik and colleagues showed 
THP-1 cells to produce IL-1α, IL-1β, IL-6, TNF-α and MCP-1 when stimulated with Aβ 
(17). Using THP-1 cells Yates et al. showed an increase in MIP-1α and MIP-1β when 
stimulated with Aβ(1-40) and LPS (44). More close to microglia are human blood 
monocytes. These cells are able to produce MIP-1α, MIP-1β and MCP-1 when stimulated 
with 50 µg/ml Aβ(1-42) for 48 h (35). In our opinion primary human monocytes-derived 
macrophages are cells most closely resembling microglia. We found MIP-1α and MIP-1β 
to be produced and due to the high production of MCP-1 in unstimulated cells no induction 
of MCP-1 by Aβ(1−42) could be found. 
As a model for astrocytes several cell types have been used. Primary rat astrocytes 
have been shown to produce MCP-1 and RANTES upon stimulation with 50 µM Aβ(1-42) 
or 50 µM Aβ(1-40) (37). The human astrocytoma cell line U373MG also produces MCP-1 
when stimulated with 30 µM Aβ(1-42) (36). Oh et al. showed U373MG also to be able to 
produce MCP-1 and RANTES (45) when stimulated with TNF-α. Using 10 µM Aβ(1−42) 
we show that primary human adult astrocytes are only capable of producing MCP-1. High 
concentration of Aβ used by others and the use of different cells might account for the 
difference in detecting RANTES. 
The overall balance of pro- and anti-inflammatory products in brains of people 
suffering from Alzheimer’s disease might play an important role in the degenerative 
process. Glial cells and more important microglia are thought to play a major role in the 
production of pro-inflammatory products. Because microglia are not present around diffuse 
plaques, chemo-attractive products might be responsible of attracting these cells towards 
the neuritic plaque. Using primary human cells we show here that CC-chemokines MIP-1α, 
MIP-1β and MCP-1 could be very good candidates accomplishing this task. 
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Table I. Sequences of the oligonucleotide primers and probes in reverse transcriptase polymerase chain reaction. 
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Target 
(Product size) 
  
Sequence (5’-3’) 
Sense CCATGGAGAAGGCTGGGG 
Antisense CAAAGTTGTCATGGATGACC 
GAPDH 
(195 bp) 
Probe CTGCACCACCAACTGCTTAGC 
Sense TGCATCACTTGCTGCTGACACG 
Antisense CAACCAGTCCATAGAAGAGG 
MIP-1α 
(333 bp) 
Probe CTGACTACTTTGAGACGAGC 
Sense CCAAACCAAAAGAAGCAAGC 
Antisense AGAAACAGTGACAGTGGACC 
MIP-1β 
(310 bp) 
Probe ACATCTCCTCCATACTCAGG 
Sense GCGAGCTATAGAAGAATCACC 
Antisense ATAAAACAGGGTGTCTGGGG 
MCP-1 
(230 bp) 
Probe GACAAGCAAACCCAAACTCC 
Sense CTTTGTCACCCGAAAGAACC 
Antisense GTTTCATCATGTTGGCCAGG 
RANTES 
(352 bp) 
Probe TTGCTCTTGTCCTAGCTTGG 
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Abstract 
 
In this study the capability of amyloid-β(1−42) to induce chemotaxis of monocytes 
towards macrophages, astrocytes, neurons and cocultures their of was investigated. 
Moreover, the involvement of CC-chemokines was studied. Results show a concentration-
dependant increase in chemotaxis of monocytes towards amyloid-β-stimulated 
macrophages. Neutralizing antibodies showed that MIP-1α, MIP-1β and MCP-1 are 
involved in this migration of monocytes. We found however no increased chemotaxis of 
monocytes towards amyloid-β-stimulated astrocytes. Cocultures showed an increased 
chemotaxis of monocytes when compared to cells alone. Amyloid-β-stimulated cocultures 
showed no increased chemotaxis when compared to unstimulated cells. Amyloid-β-
stimulated cocultures of neurons and astrocytes even showed a decreased chemotaxis. 
 
Introduction 
 
In Alzheimer’s disease (AD) degradation of neurons is eventually responsible for the 
clinical aspects. This degradation of neurons is mostly concentrated around neuritic 
plaques. These plaques are one of the hallmarks of AD and mainly consist of the 
aggregated protein amyloid-β (Aβ). In-vitro studies have shown that Aβ can be directly 
neurotoxic and thus is it therefore suggested to be partially responsible for the 
neurodegeneration (1-4). However, neuritic plaques are also reported to be surrounded by 
microglia, or so called brain macrophages, and astrocytes and these cells are known for 
their ability to produce multiple inflammatory products. Several groups have shown that Aβ 
is able to stimulate these cells to produce various pro- and anti-inflammatory products 
(reviewed in (5)). The released inflammatory molecules can not only be damaging for the 
neurons but can also stimulate nearby microglia and astrocytes and in this manner continue 
the inflammatory response. Each cell is in its own environment a target for Aβ and 
numerous other signals, eventually resulting in an unequal balance between pro-
inflammatory and anti-inflammatory responses.  
A lot of effort has been put in resolving the intracellular pathways in microglia and 
astrocytes leading to the production of these pro-inflammatory products (6-10). These 
reports also show that using specific enzyme inhibitors these pathways can be blocked, 
resulting in a decreased production of the pro-inflammatory products. This in turn may lead 
to a decreased neurodegeneration. However, little is known about the recruitment of 
microglia and astrocytes towards the plaque. Diffuse plaques are in contrast to neuritic 
plaques only surrounded by a few astrocytes and not by microglia (11). The concentration 
of glial cells around a neuritic plaques is found to be higher than elsewhere in the brain (12-
14). Understanding this mechanism might help in shifting the balance between pro- and 
anti-inflammatory molecules to the latter. Using primary human monocyte-derived 
macrophages as a model for microglia we have shown that upon Aβ stimulation these cells 
produce and express MIP-1α and MIP-1β (Smits et al., submitted). Aβ-stimulated primary 
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human astrocytes showed an increased MCP-1 production and expression. MIP-1α, MIP-
1β and MCP-1 are chemoattractant proteins belonging to the family of CC-chemokines. 
The chemokine system in humans is a superfamily of approximately 50 ligands and 20 G 
protein-coupled receptors. These ligands are divided into four families on the basis of the 
pattern of conserved cysteine residues in the aminoterminus of the proteins. Glial cells 
present around the neuritic plaque might attract other glial cells by producing the mentioned 
CC-chemokines. In this way they might be responsible for the continuation of the 
inflammatory process. The neurons however are the target cells. Their role in the 
inflammatory process is not very clear. Neurons are capable of producing chemokines and 
expressing chemokine receptors (reviewed in (15) and (16)).  
In order to study the role of neurons in the chemotaxis of glial cells and to study 
whether CC-chemokines produced by glial cells are indeed chemoattractive, this study 
reports the capability of Aβ (1-42)-induced macrophages, astrocytes to attract monocytes. 
Also cocultures of Aβ (1-42)-induced macrophages and astrocytes, astrocytes and neurons 
and macrophages and neurons were studied in their ability to attract monocytes. Moreover 
the CC-chemokines involved were identified using neutralizing antibodies. 
 
Materials and methods 
 
Materials 
The synthetic Aβ peptide Aβ (1-42) was obtained from Genosphere Biotechnologies 
(Paris, France). Gentamicin sulfate was purchased from Sigma (Zwijndrecht, The 
Netherlands). Iscove’s modified Dulbecco’s medium was obtained from Gibco Life 
Technologies (Breda, the Netherlands). Ciprofloxacin was bought from Bayer 
Pharmaceuticals (Mijdrecht, The Netherlands) and Ficoll-Paque from Pharmacia Biotech 
(Uppsala, Sweden). MIP-1α, MIP-1β and MCP-1 neutralizing antibodies were obtained 
from PeproTech (London, UK). 
 
Amyloid-β 
Lyophilized synthetic Aβ(1-42) peptide, initially dissolved at a concentration of 1 
mM in sterile double-distilled pyrogen-free water, was aliquoted and stored at –20 °C. 
 
Cells 
Monocytes were derived from peripheral blood mononuclear cells by Ficoll-Paque 
density gradients and purified by centrifugal elutriation as described previously (17). Cells 
were seeded at a concentration of 2 x 106 cells / ml in Teflon Erlenmeyer flasks (Nalgene, 
USA) and grown as suspension at 37 °C in a humidified atmosphere of 5% CO2 / 95% air. 
Culture medium was composed of Iscove’s modified Dulbecco’s medium supplemented 
with 10% (v/v) heat-inactivated human AB serum, 2 mM L-glutamine, 19 mM sodium 
bicarbonate, 10 µg/ml gentamicin and 0.5 µg/ml ciprofloxacin. After 7 days, monocyte-
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derived macrophages (MDMs) were harvested from the flasks, washed with Hanks’ 
balanced salt solution (HBSS) and used for experiments. 
Monocytes used for transwell experiments were isolated as described and labeled for 
30 min with 10 µM BCECF AM (2’, 7’-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, 
acetoxymethylester, Molecular Probes, USA). After washing 1x106 monocytes were put in 
the upper compartment of a Costar Transwell cell culture chamber. 
The human astrocytoma cell line U373 MG was obtained from ATCC and was 
grown in a humidified atmosphere of 5% CO2 / 95% air in Dulbecco’s modified eagle 
medium / Nutrient mixture Ham F-10 (Gibco Life Technologies), 1:1, supplemented with 
10% (v/v) fetal calf serum, 10 IU / ml penicillin, 10 IU / ml streptomycin and 1.2 mM L-
glutamine. 
The human neuronal cell line SK-N-MC was obtained from ATCC and was grown 
in a humidified atmosphere of 5% CO2 / 95% air in Eagle’s minimal essential medium, 
supplemented with 10% (v/v) fetal calf serum, 1 mM sodium pyruvate, 0.1 mM non-
essential amino acids, 19 mM sodium bicarbonate, 5 µg/ml ciprofloxacin and 10 µg/ml 
gentamicin. 
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Figure 1 
Chemotaxis of monocytes towards unstimulated macrophages, astrocytes and neurons. Cells were 
incubated for 24 h in the lower compartment of a Costar Transwell cell culture chamber after which labeled 
monocytes in the upper compartment separated by a microporous membrane with a pore size of 5 µM were 
allowed to migrate. After 1 h the fluorescence was measured in the lower compartment using an excitation of 485 
nm and an emission of 530 nm. *, statistically significant difference in chemotaxis of monocytes towards 
unstimulated astrocytes from unstimulated macrophages. 
 
 CC-chemokine-induced migration of monocytes 
 79 
Chemotaxis 
Costar Transwell cell culture chambers (Costar, The Netherlands) were used for 
measuring the chemotaxis of labeled monocytes in the upper compartment towards non- 
and Aβ-stimulated macrophages, astrocytes or neurons or cocultures their of in the lower 
compartment. 1 x 106 cells were stimulated, as shown in Figures 1 to 4, for 24 h in the 
lower compartment using culture medium as described above, in a humidified atmosphere 
of 5% CO2 / 95% air. Next, unstimulated or stimulated cells in the lower compartment were 
cultured with 1 x 106 labeled monocytes in the upper compartment separated by a 
microporous membrane with a pore size of 5 µM. After 1 h the fluorescence was measured 
in the lower compartment using an excitation of 485 nm and an emission of 530 nm. 
 
Statistical Analysis 
In all experiments Student-t test was used to compare unstimulated or Aβ(42-1)-
stimulated macrophages, astrocytes or cocultures thereof and Aβ(1-42)-stimulated 
macrophages, astrocytes or cocultures thereof. Reported p-values are two-sided. 
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Figure 2A 
Chemotaxis of monocytes towards Aβ(1-42)-stimulated macrophages. Cells were stimulated with 
indicated concentrations Aβ for 24 h in the lower compartment of a Costar Transwell cell culture chamber after 
which labeled monocytes in the upper compartment separated by a microporous membrane with a pore size of 5 
µM were allowed to migrate. After 1 h the fluorescence was measured in the lower compartment using an 
excitation of 485 nm and an emission of 530 nm. *, statistically significant difference in chemotaxis of monocytes 
towards 10 µM Aβ(1-42)-stimulated macrophages compared to unstimulated macrophages. 
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Results 
 
When stimulated with 10 µM Aβ(1-42), macrophages are capable of producing 
MIP-1α, MIP-1β and MCP-1 (Smits et al., submitted). To study whether or not these CC-
chemokines are involved in the chemoattractance of other glial cells towards the neuritic 
plaque, first the capability of unstimulated macrophages, astrocytes and neurons to attract 
monocytes was tested. Astrocytes showed a significant (p<0.01) increased capability of 
attracting monocytes compared to macrophages and neurons (Fig. 1). 
Next macrophages were stimulated with 1.25, 2.5, 5 and 10 µM Aβ(1-42) for 24 h 
after which the capability of attracting monocytes was tested. With an increasing 
concentration of Aβ, an increasing chemotaxis of monocytes was measured (Fig. 2A). 
Macrophages stimulated with 10 µM Aβ(1-42) showed a significant (p<0.02) increased 
capability of attracting monocytes when compared to unstimulated macrophages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2B 
Comparison of the chemotaxis of monocytes towards unstimulated and Aβ(1-42)-stimulated macrophages 
and astrocytes. Unstimulated and 10 µM Aβ(1-42) stimulated cells were incubated for 24 h in the lower 
compartment of a Costar Transwell cell culture chamber after which labeled monocytes in the upper compartment 
separated by a microporous membrane with a pore size of 5 µM were allowed to migrate. After 1 h the 
fluorescence was measured in the lower compartment using an excitation of 485 nm and an emission of 530 nm. *, 
statistically significant difference in chemotaxis of monocytes towards Aβ(1-42)-stimulated macrophages 
compared to unstimulated macrophages. 
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Figure 3 
Chemotaxis of monocytes towards unstimulated macrophages, 10 µM Aβ(1-42)-stimulated macrophages 
and 10 µM Aβ(1-42)-stimulated macrophages incubated with anti-MCP-1 (A), anti-MIP-1α (B) or anti-MIP-1β 
(C) antibody. Cells were incubated for 24 h in the lower compartment of a Costar Transwell cell culture chamber 
after which labeled monocytes in the upper compartment separated by a microporous membrane with a pore size 
of 5 µM were allowed to migrate. After 1 h the fluorescence was measured in the lower compartment using an 
excitation of 485 nm and an emission of 530 nm. *, statistically significant difference in chemotaxis of monocytes 
towards Aβ(1-42)-stimulated macrophages compared to unstimulated macrophages. **, statistically significant 
difference in chemotaxis of monocytes towards Aβ(1-42)-stimulated macrophages incubated with anti-MCP-1 
(A), anti-MIP-1α (B) or anti-MIP-1β (C) antibody compared to Aβ(1-42)-stimulated macrophages. 
 
Astrocytes are, when stimulated with 10 µM Aβ(1-42), capable of producing MCP-1 
(Smits et al., submitted). As shown in Fig. 1 unstimulated astrocytes already attract more 
monocytes than unstimulated macrophages do, so the next question was whether stimulated 
astrocytes attract more monocytes than unstimulated astrocytes like seen in macrophage 
cultures. Therefore non- and Aβ(1-42)-stimulated macrophages were compared with non- 
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and 10 µM Aβ(1-42)-stimulated astrocytes. As shown in Fig. 2B 10 µM Aβ(1-42) is able to 
activate macrophages is such a way that enhanced chemotaxis of monocytes occurs. 
Unstimulated astrocytes showed an even higher capability of attracting monocytes. 
Stimulation of astrocytes with 10 µM Aβ(1-42) did not evoke a chemotactic response. 
To identify the CC-chemokines involved in the attractance of monocytes towards 
macrophages and astrocytes, macrophages and astrocytes were stimulated with Aβ(1-42) 
and incubated for 24 h together with neutralizing antibodies directed against either MIP-1α, 
MIP-1β or MCP-1 using concentrations according to the manufacture’s instructions. Using 
anti-MCP-1 antibody, Fig. 3A shows that there is a significant (p<0.03) decrease in the 
chemotaxis of monocytes. Fig. 3B shows that there is an even stronger decrease of the 
chemotaxis when using anti-MIP-1α antibody (p<0.01). The decrease in chemotaxis of 
monocytes is not that strong (p<0.02) when using a neutralizing MIP-1β antibody (Fig. 
3C). The effect of Aβ(1-42) is almost completely abolished when compared to the effect of 
the MIP-1β neutralizing antibody. 
 
Figure 4 
Chemotaxis of monocytes towards unstimulated and stimulated with 10 µM Aβ(1-42) cocultured 
macrophages and astrocytes (m+a), neurons and macrophages (n+m) and neurons and astrocytes (n+a). Cells were 
incubated for 24 h in the lower compartment of a Costar Transwell cell culture chamber after which labeled 
monocytes in the upper compartment separated by a microporous membrane with a pore size of 5 µM were 
allowed to migrate. After 1 h the fluorescence was measured in the lower compartment using an excitation of 485 
nm and an emission of 530 nm. *, statistically significant difference in chemotaxis of monocytes towards Aβ(1-
42)-stimulated cocultures of neurons and astrocytes compared to unstimulated cocultures of neurons and 
astrocytes. 
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Neuritic plaques are not just surrounded by only microglia and degenerating neurons 
or only astrocytes and degenerating neurons, the three cells are present at the same time. 
Therefore macrophages and astrocytes, macrophages and neurons and astrocytes and 
neurons were cocultured and exposed to 10 µM Aβ(1-42) (Fig. 4). When coculturing 
macrophages and astrocytes, more monocytes are attracted to the lower compartment of the 
Transwell then when these cells are cultured apart (Fig. 1). Aβ(1-42) doesn’t influence the 
chemotaxis when compared to unstimulated cocultures. Coculturing neurons and 
macrophages increases the chemotaxis of monocytes substantial (Fig. 4). Here Aβ(1-42) 
doesn’t influence the chemotaxis either. We saw an even higher chemotaxis of monocytes 
when coculturing neurons and astrocytes (Fig. 4). When incubated with Aβ(1-42) the 
chemotaxis decreased dramatically when compared to unstimulated cocultures (p<0.01). 
 
Discussion 
 
In AD neuronal injury is partially caused by neuritic plaques. Unraveling the 
cascade of events leading to the degeneration of neurons is however very complicated. Next 
to Aβ being neurotoxic itself, it has been shown by different groups that macrophages and 
astrocytes are able to produce pro- and anti-inflammatory molecules upon stimulation with 
Aβ (18-23). The presence of these cells makes the situation much more difficult. 
Macrophages are obviously not able to clear the plaque. This might be due to the early 
presence of astrocytes around plaques. Astrocytes are already present near diffuse plaques 
and because of this early presence they probably protect the aggregated Aβ protein against 
macrophages at a later stage. Once present macrophages turn out to enhance neurotoxicity. 
The results presented here show that macrophages are able to attract monocytes and 
that Aβ-stimulated macrophages show a significant increased ability to attract monocytes. 
The use of neutralizing antibodies showed particularly MIP-1α and MIP-1β being 
responsible. MCP-1 antibodies revealed a modest but significant decrease in the chemotaxis 
of monocytes. Upon Aβ stimulation macrophages are not only able to produce and express 
MIP-1α and MIP-1β but are, together with MCP-1, produced in such amounts that 
monocytes are attracted. Interestingly astrocytes are capable of attracting an even higher 
amount of monocytes. Here, Aβ had no influence. Unstimulated neurons also showed the 
capability of attracting monocytes.  
Coculturing macrophages and astrocytes revealed a slightly higher chemotaxis of 
monocytes compared to astrocytes alone. It is however not as high as the result from 
macrophages and astrocytes alone counted together. The presence of chemokine receptors 
on the surface of astrocytes and macrophages could be an explanation. By binding 
chemokines they might effectively neutralize these chemokines, in other words disable 
them from being chemotactic. Aβ is not able to induce an even higher production of 
chemotactic molecules. There is no significant difference between unstimulated and Aβ-
stimulated cocultures. 
The highest amount of monocytes were attracted by cocultures of unstimulated 
astrocytes and neurons. Remarkably the chemotaxis dropped sharply when these cells were 
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incubated with Aβ(1-42). In the unstimulated situation astrocytes and neurons apparently 
stimulate each other in the production of chemoattractive molecules, which in turn are able 
to attract monocytes. The addition of Aβ doesn’t change the response of astrocytes, as seen 
in Fig. 2B. So the result might be due to the effect of Aβ on the neuron. Neurons appear to 
change directly upon binding of Aβ since only 24 h after addition of Aβ chemotaxis was 
measured. It is also possible that upon Aβ stimulation the astrocyte is stimulated to produce 
a factor that inhibits the production of chemokines by the neurons. In both ways the 
chemokine involved has to bind to the receptors expressed on the monocyte. Monocytes are 
reported to express the CC-chemokine receptors CCR1, CCR2 and CCR5, the CX3C 
receptor and the CXCR4 receptor.  
Coculturing unstimulated macrophages and neurons revealed a remarkable increase 
in the chemotaxis of monocytes when compared to induction of chemotaxis by one of these 
cells alone. In contrast to cocultured astrocytes and neurons, incubating these cocultures 
with Aβ brought no significant difference in the chemotaxis. So the effect of Aβ on the 
chemotaxis of monocytes in cocultured neurons and astrocytes might not be due to the 
effect of Aβ on the neuron itself. It seems more likely that a factor produced by the 
astrocytes is responsible. To resolve the question whether the decrease in chemotaxis in 
cocultured astrocytes and neurons is due to the effect of Aβ on the neuron or due to a 
inhibiting factor produced by astrocytes remains to be investigated. 
When comparing the results of the cocultures with the in-vivo situation one should 
have in mind that in the brain the formation of neuritic plaques is a process of many years 
and that during this period the involved cells interact with Aβ and each other. Obviously it 
is very difficult to mimic this situation in a relevant human in-vitro model. 
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Ever since Glenner and Wong (1) found Aβ to be the major component of neuritic 
plaques and McGeer et al. found activated microglia to be concentrated around these 
plaques (2) one has questioned the cascade of events leading to neuronal death. The 
research presented in this thesis addresses several issues of this cascade of events. Using 
primary human monocyte-derived macrophages as model cells for microglia and primary 
human adult astrocytes as well as U373 astrocytoma’s as model cells for astrocytes the role 
of these cells in the inflammatory process and the continuation of this process was 
investigated. In summary the results presented in chapter 2 show the effect of Aβ(25-35) on 
the binding of Aβ(1-42) to macrophages and the consequent superoxide anion production. 
Aβ(25-35) markedly enhanced the effect of Aβ(1-42). Chapter 3 shows that both ERK 1/2 
and p38 MAPK signal transduction pathways as well as PKC are involved in the amyloid-
β-stimulated superoxide anion production in macrophages. In contrast, only ERK 1/2 
MAPK seems to be involved in TNF-α production, questioning the connection between 
PKC and ERK 1/2 activation. Chapter 4 shows that Aβ is able to induce TNF-α and 
superoxide anion production in macrophages and that astrocytes do not produce these 
inflammatory mediators. In cocultures however a decreased production of these putative 
neurotoxins was seen, probably due to the binding of Aβ to the astrocytes. Aβ is able to 
induce NF-κB activation in astrocytes. However, due to the already high NF-κB activity in 
macrophages, an additional effect of Aβ could not be detected. Chapter 5 shows the ability 
of Aβ(1-42) to stimulate the production, and expression of MIP-1α and MIP-1β in 
macrophages and MCP-1 in astrocytes and in cocultures their of. In chapter 6 the 
effectiveness of these CC-chemokines to attract monocytes was investigated. Using 
neutralizing antibodies it was shown that Aβ-stimulated macrophages produce MIP-1α, 
MIP-1β and MCP-1 in such amounts that they attract monocytes. 
 
Overall the results show that there are many elements that may be involved in the 
course of inflammation. One way or another, the cascade of events will lead to a local 
inflammatory reaction and although inflammatory reactions are almost always a secondary 
reaction, it is as important as the mechanism that gave rise to it. The inflammatory elements 
must be produced by local cells because in Alzheimer’s disease the blood-brain barrier is 
intact. In case of the brain, these are the neurons, astrocytes, microglia and 
oligodendrocytes. Of these four cell types the latter is not involved in the pathology of the 
neuritic plaque in Alzheimer’s disease. A first question then might be why are microglia 
and astrocytes located around these plaques? As simple as the question is, it is very hard to 
answer. A more important question might be how do these cells get there? Answering this 
question could resolve a lot of problems. Chapter 5 and 6 show that CC-chemokines very 
likely play an important role. As important as these chemokines might be, produced by glial 
cells and attracting other glial cells, it just shows that glial cells are likely to be responsible 
for the continuation of the inflammatory process. Trying to intervene in the chemotaxis of 
glial cells towards the plaque might indeed slow the inflammatory response and therefore 
the neuronal loss. Problem is that chemokines and other proteins responsible for this 
chemotaxis are not unique in that they are only functional around the plaque. Therefore, 
preventing or slowing chemotaxis of glial cells through this mechanism is at this moment 
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not an option. Identifying a protein unique in attracting glial cells towards the plaque might 
bring a solution.  
 
CC-chemokines might play an important role in attracting more glial cells towards 
the neuritic plaque, it still doesn’t answer the question why glial cells are located around 
plaques in the first place, does it? Yet, diffuse plaques are reported to be surrounded by a 
few reactive astrocytes (3) and not by microglia (4). Furthermore, astrocytes are stated to 
express CC-chemokine receptors CCR1, CCR2 and CCR5, making them able to bind MCP-
1, MIP-1α and MIP-1β (5,6). Chapter 5 shows that astrocytes are able to produce MCP-1 
upon incubation with Aβ. Thus astrocytes present around a diffuse plaque are able to attract 
other astrocytes and in this way may be responsible for the large amount of reactive 
astrocytes that are eventually present around the neuritic plaque. If the astrocytes around 
the diffuse plaques produce MCP-1 it apparently does not attract microglia. This might be 
due to the fact that macrophages/microglia produce high amounts of MCP-1 themselves 
and therefore are not as reactive towards MCP-1 as astrocytes do. It is not known how the 
few astrocytes around the diffuse plaque are attracted to this plaque. One possible answer 
might be that Aβ seems to have chemotactic properties itself (7).  
 
Studying inflammation in Alzheimer’s disease is made difficult by the obvious fact 
that human brains are not as accessible as peripheral organs are. There are two ways to 
overcome this problem. One way is the use of animal models, the other way is the use of in-
vitro systems. The use of both methods may be required in understanding the role of the 
astrocyte in the neuritic plaque. This role seems contradictory. On one hand they appear to 
prevent macrophages/microglia from clearing the Aβ deposit and, as shown in chapter 4, 
attenuate the Aβ-induced inflammatory response of these macrophages/microglia. On the 
other hand they are, in-vitro and in-situ, capable of producing numerous inflammatory 
components themselves (for a list see (8)). In the use of animal models the overexpression 
of cytokines in transgenic mice using astrocyte-specific promoters revealed profound 
biological influences of these molecules in the CNS. Using the GFAP promoter it has been 
shown that for example the overexpression of TNF-α leads to chronic and severe 
inflammation in the CNS (9,10). It may be apparent that this use of astrocyte-specific 
promoters doesn’t mean that cytokine mechanisms aren’t that important in microglia. 
Microglia clearly express cytokines and chemokines, but are so closely related to peripheral 
macrophages that it is difficult to imagine a microglia-specific promoter that would not lead 
to expression of a cytokine or chemokine different than macrophages would do throughout 
the body. Other animal models are based on human FAD APP and/or FAD PS-1 mutations. 
Brains of mice carrying both mutant genes develop AD-like deposits composed of Aβ 
which at an later age are surrounded by activated microglia and astrocytes (11-13). 
Problems with these animal models are the lack of neurofibrillary tangles and, more 
important, little or no neuronal loss. However, the development of these models is very 
important. More complex models may in the future be essential in the testing of therapeutic 
agents. Developing therapeutic agents on basis of the inflammatory process in AD, thereby 
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using complex animal models, requires every part of the process to be comprehendible. In-
vitro systems are ideal in that simplifying complex models is rather easy. The use of in-
vitro studies in this thesis partially clarified the role of the macrophage/microglia in the 
production of some pro-inflammatory molecules. Shifting the balance between pro- and 
anti-inflammatory molecules to the latter might be a good alternative in slowing 
Alzheimer’s disease. 
 
Another alternative and may be the only alternative in stopping or preventing the 
disease is interfering at the very beginning. β-Secretase and γ-secretase are essential in 
cleaving APP, thereby giving rise to Aβ. By neutralizing these secretases very early in the 
disease, Aβ might be prevented from coming into existence. There are however some 
problems that need to be addressed. First the identification of the secretases, only recently 
five different groups using three different approaches independently found BACE (also 
known as Asp2 or Memapsin2) to be β-secretase. In addition, it has been shown that BACE 
is a membrane-bound aspartyl protease that fulfils all possible criteria for β-secretase (14-
18). The identification of γ-secretase may be even more important, since this enzyme is 
responsible for the Aβ releasing cut. Although there is strong evidence for presenilin-1 
being γ-secretase (19-22), the working mechanism is still not clear. There are some reports 
suggesting that γ-secretase most likely is a complex of proteins of which presenilin-1 is a 
part of (23-25). Another important issue is whether these secretases have other functions 
next to processing APP. Presenilins are known to be important in processing Notch for 
example (26-28). Whether or not these secretases are the ideal targets for drug 
development, in the development of any drug two more problems need to be solved. First in 
AD the blood-brain barrier is intact. Drugs being developed must be able to pass this 
barrier. The second problem is age of onset. For the neuritic plaque to develop and to be 
neurotoxic takes several years to decades. Therefore people who will get AD when at an 
older age already need this drug at an early age. In this way the plaque is being prevented 
from developing. To administer a drug to a person who will get AD at a later age requires 
the ability to diagnose AD at an early age. And at the moment this is not possible. 
Therefore more preclinical and clinical research is warranted towards drug development for 
AD. 
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De meest voorkomende vorm van dementie is de ziekte van Alzheimer. 
Kenmerkend is de steeds erger wordende vergeetachtigheid. Deze vergeetachtigheid wordt 
veroorzaakt door het afsterven van hersencellen. In tegenstelling tot veel andere cellen in 
het lichaam worden deze hersencellen, met de naam neuronen, niet vervangen na het 
afsterven. Blijkbaar zijn de neuronen die afsterven betrokken bij het geheugen en treedt na 
het afsterven van veel neuronen geheugenverlies op. 
Een heel specifiek kenmerk in de hersenen van patiënten die lijden aan de ziekte van 
Alzheimer is de plaque. Deze plaque is een opeenhoping van een eiwit met de naam 
amyloid-beta (Aβ). Rondom deze plaque vindt het afsterven van neuronen plaats. Er is 
echter nog een belangrijke component. Het is gebleken dat deze plaques omringd worden 
door niet-neuronale hersencellen. Deze gliale cellen, genaamd astrocyt en microglia, liggen 
met velen rondom de plaque. De centrale vraag in dit proefschrift is: wat is de rol van de 
microglia en de astrocyt in het afsterven van neuronen? 
De microglia, ook wel hersenmacrofaag genoemd, is in staat veel verschillende 
toxische stoffen te maken. Een van die stoffen is het zuurstofradicaal. Hoofdstuk 2 laat zien 
dat door binding van het eiwit Aβ aan de macrofaag, deze macrofaag gestimuleerd wordt in 
de productie van deze zuurstofradicalen. Eerder onderzoek heeft al uitgewezen dat 
verschillende onderdelen van het eiwit Aβ verantwoordelijk zijn voor verschillende 
functies van het eiwit. In hoofdstuk 2 is de macrofaag ook nog gestimuleerd met een 
mengsel van Aβ zelf en een van die onderdelen. Dit onderdeel zelf kan niet aan de 
macrofaag binden, echter door het mengsel van Aβ en dit onderdeel maakt de macrofaag 
veel meer van het toxische zuurstofradicaal. De experimenten laten zien dat dit komt 
doordat in het mengsel meer van het Aβ eiwit bindt aan de macrofaag dan wanneer het Aβ 
alleen aan de macrofaag wordt toegevoegd. 
Er worden door macrofagen niet alleen zuurstofradicalen gemaakt wanneer deze 
worden gestimuleerd met Aβ maar ook andere producten. Hoofdstuk 3 laat zien dat 
macrofaag stimulatie met Aβ ook resulteert in de productie van TNF-α. Om beter te 
kunnen begrijpen hoe het komt dat de macrofaag na toevoeging van Aβ TNF-α en 
superoxide radicalen gaan maken zijn er een aantal experimenten uitgevoerd waar is 
gekeken naar de signaalwegen in de macrofaag, die bij dit proces betrokken zouden kunnen 
zijn. Wanneer dit specifieke signaalwegen zijn dan zouden deze eventueel geremd kunnen 
worden. Dit zou een mogelijkheid kunnen zijn om de macrofaag minder toxische stoffen te 
laten maken wat weer tot gevolg zou kunnen hebben dat minder neuronen om de plaque 
afsterven. De resultaten in hoofdstuk 3 laten inderdaad zien dat bepaalde intracellulaire 
signaalwegen betrokken zijn bij de produktie van TNF-α en superoxide radicalen. In het 
laboratorium kunnen deze signaalwegen specifiek geblokeerd worden waarbij er een 
verminderde produktie van TNF-α en superoxide radicalen gemeten werd.  
Naast microglia bevinden zich rondom de plaque ook astrocyten. De rol van deze 
astrocyten is echter nog niet duidelijk. Hoofstuk 4 laat zien dat ze na stimulatie met Aβ in 
tegenstelling tot macrofagen geen TNF-α en superoxide radicalen maken. Omdat de 
microglia en astrocyt rondom de plaque naast elkaar aanwezig zijn is dit in het laboratorium 
ook gedaan. Het samen kweken van macrofagen en astrocyten laat zien dat wanneer 
gestimuleerd wordt met Aβ er een duidelijk verminderde productie van TNF-α en 
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superoxide radicalen plaats vindt in vergelijking met macrofagen alleen. Het lijkt er dus op 
dat de astrocyt de macrofaag remt in de productie van deze toxische stoffen. Verdere 
resultaten in hoofstuk 4 laten zien dat dit waarschijnlijk komt door binding van Aβ aan de 
astrocyt in plaats van aan de macrofaag. 
 
Een belangrijke vraag in het ziekteproces is hoe komen zoveel gliale cellen rondom 
die plaque te liggen. De dichtheid aan gliale cellen rondom de plaque is veel groter dan 
ergens anders in de hersenen. Nu is van sommige eiwitten bekend dat ze cellen kunnen 
aantrekken. Enkele van deze eiwitten worden gemaakt door gliale cellen en zijn in staat 
ander gliale cellen aan te trekken. Deze specifieke groep van attractieve eiwitten worden  
CC-chemokines genoemd. In hoofdstuk 5 is gekeken naar de mogelijkheid van macrofagen 
en astrocyten om na activatie met het eiwit Aβ deze CC-chemokines te maken. Zowel op 
RNA niveau in de cel alsmede op eiwit niveau in het kweekmedium van de macrofagen is 
aangetoond dat er een verhoogde productie is van twee van deze CC-chemokines, genaamd 
MIP-1α en MIP-1β. De astrocyt laat een verhoogde productie van een ander CC-
chemokine zien, het MCP-1. Omdat deze gliale cellen in patiënten met de ziekte van 
Alzheimer naast elkaar aanwezig zijn, hebben we dit in het laboratorium nagebootst. Doel 
hiervan was om te kijken of de astrocyt invloed heeft op de productie van CC-chemokines 
door de macrofaag en andersom. Dit bleek niet het geval. In kweken van macrofagen en 
astrocyten samen is in het kweekmedium zowel MIP-1α, MIP-1β alsmede MCP-1 
gevonden. Deze experimenten hebben aangetoond dat gliale cellen in staat zijn om CC-
chemokines te maken. Deze attractieve eiwitten zouden een belangrijke rol kunnen spelen 
in het aantrekken van andere gliale cellen naar de plaque. 
In hoofdstuk 6 is dit onderzoek voortgezet door te kijken of deze door de macrofaag 
en astrocyt gemaakte chemokines in zulke hoeveelheden worden gemaakt dat deze in staat 
zijn om andere cellen daadwerkelijk aan te trekken. In het laboratorium werden monocyten, 
de voorlopercellen van de macrofaag, gebruikt voor dit doeleinde. De resultaten laten zien 
dat als macrofagen worden gestimuleerd met een steeds hoger wordende concentratie Aβ er 
ook steeds meer migratie plaats vindt van monocyten naar de macrofaag. Dat betekent dat 
macrofagen niet alleen chemokines of andere attractieve eiwitten maken maar dat deze in 
zulke hoeveelheden gemaakt worden dat er daadwerkelijk cellen in staat zijn naar deze 
macrofaag toe te migreren. In een zelfde situatie hebben we gekeken naar de astrocyt. Deze 
maakt onder invloed van Aβ immers MCP-1. Het blijkt dat ook de astrocyt in staat is 
monocyten aan te trekken. Dit gebeurt echter ook al wanneer de astrocyt niet wordt 
gestimuleerd door Aβ. Om de factoren die belangrijk zijn bij de migratie van deze 
monocyten naar de macrofaag te identificeren hebben we gebruik gemaakt van 
antilichamen. Specifieke antilichamen voor MIP-1α, MIP-1β en MCP-1 kunnen de werking 
van deze blokkeren. De resultaten laten zien dat er inderdaad een verminderde tot sterk 
verminderde migratie plaats vindt van monocyten naar de macrofaag wanneer deze 
antilichamen worden gebruikt. Dat betekent dat MIP-1α, MIP-1β en MCP-1 betrokken 
zouden kunnen zijn bij de migratie van gliale cellen naar de plaque. 
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